Protocol number : 13-077 
 
 
Official Title of the study : A Phase [ADDRESS_266353] Cancer:  Evaluation of Efficacy, Toxicity, and Patient-
Reported Outcomes 
 
NCT number : [STUDY_ID_REMOVED] 
 
Date of the document: February 23, 2016  
Status Page 
 
 
 
PROTOCOL 13-077 
 
 
 
    
                                                           
 
Closed To New Accrual  
 
              
 
 
 
 
  
 
  
Closure Effective Date:  04/15/2016 No new subjects may be  enrolled in the study as described above.  
Any questions regarding this closure should be directed to the 
study’s Principal Investigator 
 
 
 
[CONTACT_3490] 1 of 1 
Date Submitted: [09/04/13]  
Date Posted: [09/09/13]  
Alert Page   
DF/HCC Protocol #:  [13-077]  
 
Revised: 07.01.13 Protocol Clarifications (non-drug rela ted e.g. eligibility criteria, study 
assessments) 
 
Protocol 5.5.2, Assessments in the Treatment Phase, page 22: Provider 
Reported CTCAE Form should be completed by [CONTACT_28839], NP /PA or Research Nurse 
the same day patients complete the QOL  surveys (C1D1, C2D1, C3D1, and then 
day 1 of every other cycle). Please note: 1. Please include the following information when completing the Provider 
Reported CTCAE Form: Subject MRN, subject initials, date, visit #, and 
provider name [CONTACT_120254].  This information is missing from the form on 
page 34 (table 2) and page 80 (Appendix 8). [Amendment forthcoming] 
2. Provider reported CTCAE assessment is missing from Section 9, Table 3: 
Study Calendar. [Amendment forthcoming]  
 
Protocol Section 9, Table 3:  Study Calendar, page 37: Tumor assessment 
must be performed every 9 weeks (within 1 week prior to C4D1, C7D1, C10D1, 
etc) during study treatment  until PD is documented. That is, Cycle [ADDRESS_266354]. [Amendment 
forthcoming]   
DFCI Protocol No: 13-077
Front Sheet
11/10/2017 09:23 AM Report Generated:
A Phase [ADDRESS_266355] Cancer: Evaluation of Efficacy,
Toxicity and Patient-Reported OutcomesTitle:
Overall Principal Investigator [INVESTIGATOR_221779], Erica L [EMAIL_4370] Dana-Farber Cancer InstituteOverall Institution: Dana-Farber Cancer Institute
Primary Contact(s) for Questions Email Phone
Andrews, Chelsea [EMAIL_4371].e
du617-632-6210
Kelley, Cassidy Elizabeth [EMAIL_4372] 2-3548Site Responsible PI(s) Email Institution
Briccetti, Frederick [EMAIL_4373] Dana-Farber Cancer Institute at NHOH
Constantine, Michael [EMAIL_4374].
eduDana-Farber Cancer Institute at Milford
Faggen, Meredith G [EMAIL_4375]
uDana-Farber Cancer Institute at South
Shore
Tung, Nadine [EMAIL_4376] Beth Israel Deaconess Medical Center
Total Study-Wide Enrollment Goal: 90 Total DF/HCC Estimated Enrollment Goal: 90
Phase: II
Age: Adults
Age Ranges: 18+
Will all subjects be recruited from pediatric clinics?
CTEP Study: No
Management Group(s): Primary Management Group: DF/HCC Breast Cancer BIDMC Breast Cancer
DF/HCC Affiliate Site
DF/HCC Breast Cancer
DF/HCC Satellite Site
DFCI/BWH Breast Oncology
OTHER Registering SiteSponsor Name [CONTACT_221860](s)
DF/HCC Investigator Regulatory
Dana-Farber/Harvard Cancer Center Funding
Eisai Funding
Investigational Drug? Yes
Drug(s), Biologic(s): E7389
IND #:
IND Holder Type:
IND Holder Name:117840
DF/HCC Investigator
Erica Mayer, MD, MPH
Investigational Device? This study does not use an Investigational Device.
Risk Category: Greater Than Minimal Risk
Chemotherapy; Human Material Collection; Questionnaires/Surveys/Interviews; Radiological Protocol Involves:IRB of Record:
11/10/2017 09:23 AM Report Generated:
Exams
Date Range: (Medical Record Review and Specimen Collection studies)
Participating Sites under the DFCI IRB
Institution: Beth Israel Deaconess Medical Center
Brigham and Women's Hospi[INVESTIGATOR_221780]-Farber Cancer Institute
Dana-Farber Cancer Institute at Milford
Dana-Farber Cancer Institute at NHOH
Dana-Farber Cancer Institute at South Shore
Participating Institutions Under Other IRB
Institution: Eastern Maine Medical Center Location: BANGOR, ME
Page 1 of 1 
 Protocol Number:  13-077 
 
Approval Date:    04/02/13  (IRB meeting date when protocol/consent  
 approved or conditionally approved)  
 
Activation Date:    05/14/13  (Date when protocol open to patient entry)  
 
Approval signatures  are on file in the Office for Human Research Studies , tel. [PHONE_4697]. 
 
Date  
Posted  Revised Sections  IRB 
Approval  
Date  OHRS  
Version 
Date  
05/17/13  Delayed Activation: BIDMC ready. All sites now active.  N/A N/A 
06/27/13  Front Sheet replaced due to Amendment # 3  06/20/13  N/A 
08/06/13  Front Sheet replaced due to Amendment # 4  08/05/13  N/A 
09/09/13  Alert Page added due to Amendment #5  09/04/13  N/A 
10/03/13  Protocol and Front Sheet replaced due to Amendment 
#6 09/26/13  N/A 
03/05/14  DF/BWCC at DFCI@Milford, DF/BWCC at DFCI 
@SSH, DFCI @ NHOH sites added; DFCI @ FH 
removed; Consent Form and Front Sheet replaced due 
to Amendment #7  03/04/14  03/05/14  
03/20/14  Study renewal/ Consent Form  footer replaced due to 
Continuing Review # 1 03/13/14  n/a 
04/14/14  Front Sheet replaced due to Amendment #8 04/14/14  n/a 
07/21/14  Protocol and Front Sheet replaced due to Amendment 
#9 07/21/14  N/A 
03/03/15  Study renewal/ Consent Form  footer replaced due to 
Continuing Review # 2 02/26/15  N/A 
03/03/15  Partial  Closure : Cohort 1 closed to New Accrual: 
accrual goal met (effective date:  02/27/15; Amendment 
#10; Cohort 2 remains open)   02/27/15  N/A 
04/14/15  Protocol and Front Sheet replaced due to Amendment 
#11 04/03/15  N/A 
Date  
Posted  Revised Sections  IRB Approval  
Date  OnCore  
Version Date  
12/09/15  Front Sheet r eplaced due to Amendment #12  12/08/15  N/A 
02/25/16  Study renewal/ Consent Form footer replaced due to 
Continuing Review # 3 02/25/16  02/25/16  
04/13/[ADDRESS_266356]  replaced due to Amendment # 13 02/25/16  n/a 
04/13/[ADDRESS_266357] and Front Sheet replaced 
due to Amendment # 14 02/26/16  n/a 
04/22/16  Permanent Closure to New Accrual: slow accrual  
(effective date: 04/15/16 ; Amendment # 18) 04/14/16  N/A 
01/19/17  Study renewal, Consent Form removed due to Data 
Analysis Only per Contin uing Review #4  12/29/16  N/A 
11/14/2017  Front Sheet replaced per Amendment #19  11/07/2017  N/A 
11/16/2017  Study Renewal per Continuing Review #5  11/09/2017  N/A 
    
    
 
 
 
     
1 
 Protocol Version Date: February 23, 2016  
 
 
Local Protocol #:13-077   
 
Title: A Phase [ADDRESS_266358] Cancer: 
Evaluation of Efficacy, Toxicity, and Patient-Reported Outcomes 
 Coordinating Center: Dana-Farber Cancer Institute 
 
Principal Investigator 
[INVESTIGATOR_193494] L. Mayer MD MPH 
Dana-Farber Cancer Institute 
Breast Oncology Center 
[ADDRESS_266359] 
[LOCATION_011], MA [ZIP_CODE] 
P [PHONE_3401] 
F [PHONE_3402] 
 
Co-Investigators 
Nancy U. Lin MD 
Breast Oncology Center 
Dana-Farber Cancer Institute 
[ADDRESS_266360] [LOCATION_011], MA [ZIP_CODE] 
P [PHONE_4698] 
F [PHONE_3402] 
 
Otto Metzger Filho MD 
Breast Oncology Center 
Dana-Farber Cancer Institute 
[ADDRESS_266361] 
[LOCATION_011], MA [ZIP_CODE] 
P [PHONE_4698] 
F [PHONE_3402] 
 
Harold J. Burstein MD PhD 
Breast Oncology Center 
Dana-Farber Cancer Institute 
[ADDRESS_266362] 
[LOCATION_011], MA [ZIP_CODE] 
2 
 P [PHONE_4698] 
F [PHONE_3402] 
 
Biostatistician  
Anita Giobbie-Hurder 
Department of Biostatistics  and Computational Biology 
Dana-Farber Cancer Institute [ADDRESS_266363]. (CLS [ZIP_CODE]) 
[LOCATION_011], MA [ZIP_CODE] 
Ph: [PHONE_4699] 
Fax: [PHONE_4700] 
 
Study Coordinator 
Danielle Gore 
Dana-Farber Cancer Institute 
[ADDRESS_266364]. 
[LOCATION_011], MA [ZIP_CODE] 
P [PHONE_4701] 
F [PHONE_3406] 
 
Director of DF/HCC Survey Core 
Carol Lowenstein 
DFCI LW601 
Dana-Farber Cancer Institute [ADDRESS_266365] 
[LOCATION_011], MA [ZIP_CODE] 
P [PHONE_4702] 
 
Responsible Research Nurse:   
Elizabeth Kasparian, RN Dana-Farber Cancer Institute 
[ADDRESS_266366] 
[LOCATION_011], MA [ZIP_CODE] 
P [PHONE_3407] 
F [PHONE_3408] 
 
Agent(s):  Eribulin mesylate (E7389)  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
3 
  
STUDY SCHEMA  
 
Abbreviations: CR, complete response; CT, chem otherapy; MBC, metastat ic breast cancer; PD, 
progressive disease; PR, partial response; SD, stable disease.  
 
 
 
 
 
 
 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
4 
 		
Table	 of	Contents	
1. OBJECTIVES .................................................................................................................... ................................ 8  
1.1.  Study De sign ............................................................................................................................................... 8  
1.2.  Primary Obje ctives ............................................................................................................ ......................... 8  
1.3.  Secondary Ob jectives .......................................................................................................... ....................... 8  
2. BACKGROUND ................................................................................................................................................ 9  
2.1.  Study Agent - Eribulin ........................................................................................................ ........................ 9  
2.2.  Study Disease.................................................................................................................. .......................... 10  
2.3.  Rationale for Correlative Studies – Patient Reported  Outcomes ............................................................. 11  
2.4.  Rationale for Correlative Studies – Single Nu cleotide Polymorphisms and Neurotox icity ...................... 13  
2.5.  Rationale fo r Study ........................................................................................................... ........................ 14  
3. PARTICIPANT SELECTI ON ......................................................................................................... ............... 15  
3.1.  Eligibility Cr iteria .......................................................................................................... .......................... 15  
3.2.  Exclusion Cr iteria .................................................................................................................................... 16  
3.3.  Inclusion of Minorities and Other Un derrepresented Populations .......................................................... 17  
4. REGISTRATION PROCEDURES ....................................................................................................... ......... 18 
4.1.  General Guidelines for DF/H CC and DF/PCC In stitutions ..................................................................... 18  
4.2.  Registration Process for DF/H CC and DF/PCC Institutions ................................................................... 18  
4.3.  Registration Process for Ot her Investiga tive Sites ............................................................................ ....... 19 
5. TREATMENT PLAN ................................................................................................................ ...................... 19  
5.1.  Overall Study Desi gn and Plan ................................................................................................. ............... 19  
5.2.  Pretreatment  Crite ria ......................................................................................................... ...................... 21  
5.3.  Treatment Phase ............................................................................................................... ........................ 22  
5.4.  Agent Admini stration ................................................................................................................................ 22  
5.5.  Schedule of Visits  and Procedures ............................................................................................. .............. 23  
5.6.  General Concomitant Medication an d Supportive Care Guidelines ........................................................ 27  
5.7.  Duration of Therapy ........................................................................................................... ...................... 29  
5.8.  Duration of Follow Up ............................................................................................................................. 29  
5.9.  Criteria for Removal from Study ............................................................................................... ............... 29  
6. EXPECTED TOXICITIES AND DO SE/DELAYS MODIFICATION ....................................................... 30  
6.1.  Eribulin – Expect ed toxi cities ................................................................................................ ................... 30  
6.2.  Eribulin - Toxic ity Manag ement ................................................................................................ ............... 31  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266367].......................................................................................................... ........... 41 
10.1. Efficacy Assessments (Antitumor Activity) ..................................................................................... .......... 41 
10.2. Baseline Identification of Target and Nontarget Lesions ....................................................................... .. 42 
10.3. Primary efficacy variable/endpoint .......................................................................................................... [ADDRESS_266368] (IRB) ............................................................................. ...... 48 
11.3. Reporting to Hospi[INVESTIGATOR_98856] ......................................................................................... ......... 49 
11.4. Reporting SAEs  to EISAI ....................................................................................................... ................... 49  
11.5. Monitoring of Adverse Events and Period of Observa tion ....................................................................... 49 
12. DATA AND SAFETY MONITORING .................................................................................................... ...... 50 
12.1. Data Repo rting ................................................................................................................ ......................... 50  
12.2. Safety Mee tings  ......................................................................................................................................... 50  
12.3. Monito ring ................................................................................................................................................ 51  
12.4. Multicenter Gu idelines ........................................................................................................ ..................... 51  
13. REGULATORY CONS IDERATIONS ..................................................................................................... ..... 52 
13.1. Protocol Review and Amendm ents ................................................................................................ ........... 52 
13.2. Informed Consent .............................................................................................................. ....................... 52  
13.3. Ethics ........................................................................................................................................................ 52  
13.4. Study Docume ntation ........................................................................................................... ..................... 53  
13.5. Records Re tention ............................................................................................................. ........................ 53  
14. STATISTICAL METHODS ........................................................................................................... ................ 54  
14.1. Statistical and An alytical Plans .............................................................................................. .................. 54  
14.2. Determination of sample size .................................................................................................. ................. 54  
14.3. Safety anal ysis ............................................................................................................... ........................... 56  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266369] v 1. 1 for Evaluation of Tumor Response ........................................... 61  
17.2. Appendix 2 - ECOG Perfor mance Status Scale .................................................................................... .... 67 
17.3. Appendix 3 - Cockcroft and Gault Formula ...................................................................................... ....... 68 
17.4. Appendix 4 - [LOCATION_001] Heart Associa tion Cardiac Disease Classifica tion ............................................. 69  
17.5. Appendix 5 - Common Terminology Criteria for Adverse Events (version 4.0) ....................................... 70  
17.6. Appendix 6 – Quality  of Life  Surveys .......................................................................................... ............. 71  
17.7. Appendix 7 - Blood Sampling for Pharmacogenomics Analysis ............................................................... 80  
17.8. Appendix 8: Provider -Reported CTCAE Form....................................................................................... .. 82 
APPENDIX 9: DF/HCC Multi-Center Data  and Safety M onitoring Plan .............................................................. 83 
1. INTRODUCTION .................................................................................................................. .......................... 85  
1.1.  Purpose ....................................................................................................................... .............................. 85  
1.2.  Multi-Center Data and Safety Monitoring Plan Definitions  .................................................................... 8 5 
2. GENERAL ROLES AND RE SPONSIBILITIES.......................................................................................... 86  
2.1.  DF/HCC Sp onsor ................................................................................................................ ..................... 86  
2.2.  Coordinating Center ........................................................................................................... ...................... 87  
2.3.  DF/HCC Quality Assurance Office fo r Clinical Trials (QACT) ............................................................... 87  
2.4.  Participating Institu tion ..................................................................................................... ...................... 87  
3. DF/HCC REQUIREMENTS FOR MULTI-CENTER PROTOCOLS ....................................................... 88  
3.1.  Protocol Di stribution ................................................................................................................................ 88  
3.2.  Protocol Revisions  and Closures ............................................................................................... ............... 88  
3.3.  Informed Consent Requirements ................................................................................................. .............. 89  
3.4.  IRB Docume ntation ............................................................................................................. ..................... 89  
3.5.  IRB Re-Approval ...................................................................................................................................... 90  
3.6.  Participant Confiden tiality and Authoriz ation Statement ......................................................................... 90  
3.7.  DF/HCC Multi-Center Protocol Registra tion Po licy .............................................................................. . 90 
3.8.  DF/HCC Protocol Case Number ................................................................................................... ........... 92 
3.9.  Protocol Deviations, Excep tions and Vi olations ................................................................................ ...... 92 
3.10. Safety Assessments and Toxicity Mo nitori ng .................................................................................... ........ 93 
3.11. Data Management ............................................................................................................... ..................... 94  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
7 
 4. REQUISITIONING DRUG ........................................................................................................... ................. 95  
5. MONITORING: QUALITY CONTROL ................................................................................................... ... 95 
5.1.  Ongoing Monitoring of Protocol Co mpliance ..................................................................................... ..... 95 
5.2.  Evaluation of Participatin g Institution Pe rformance ........................................................................... .... 95 
6. AUDITING: QUALITY ASSURANCE ................................................................................................... ...... 96 
6.1.  DF/HCC Sponsored  Trials ....................................................................................................... ................ 96  
6.2.  Participating Institu tion ..................................................................................................... ...................... 96  
6.3.  DF/HCC Sponsor and Co ordinating Center ........................................................................................ .... [ADDRESS_266370] Performance ...................................................................................................... ................ 97  
 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266371] cancer . Patients will be enrolled in 2 parallel 
cohorts. Cohort 1: Hormone receptor (HR)-positiv e /HER2-negative (HR+/HER2-). Cohort 2: 
HR-negative/HER2-negative (triple negative brea st cancer [TNBC]). A total of 45 patients will 
be included in the HR-positive c ohort and 45 in the TNBC cohort.  
1.2. Primary Objectives 
 To evaluate the antitumor activity of first-line treatment with single-agent eribulin mesylate 
in subjects with locally recurrent or me tastatic HER2-negative breast cancer by 
[CONTACT_221813] (ORR) (R ECIST version 1.1). ORR will be estimated 
separately for the HR+/HER2- an d the TNBC monotherapy cohorts. 
1.3. Secondary Objectives 
Efficacy Endpoints:  
 Progression-free survival  
 Time to first response  
 Duration of response  
 Time to first response and duration of response  
Safety Endpoints  
 To assess the safety and tolerability of single- agent eribulin mesylate (Both cohorts will be 
combined for these analyses) 
Quality of Life (QOL) Analyses  (Both cohorts will be comb ined for these analyses) 
 To describe the adverse event (AE) profile  of eribulin, accordi ng to provider-rated 
CTCAE v.4.0.  
 To describe QOL at baseline and over time using the Functional Assessment of Cancer 
Therapy-Breast (FACT-B).  
 To describe the impact of neurotoxicity on QOL at baseline and over time using the 
FACT-Neurotoxicity Subscale (FACT-Ntx). 
 To describe the profile of pa tient-reported symptomatic toxic ities experienced by [CONTACT_221814] e Patient Reported Outc ome (PRO) Version of 
the Common Terminology Criteria for Adverse Events (PRO-CTCAE).  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
9 
  To compare FACT-B, FACT-Ntx and PRO-CTCA E toxicity data with provider-reported 
CTCAE toxicity to determine degree of conc ordance or divergence for each class of 
toxicity.  
Correlative Science:  
 To explore the association between Singl e Nucleotide Polymorphisms (SNPs) and 
neurotoxicity. For this analysis, the two cohorts will be combined. 
 To collect a repository of blood sample s at baseline for future research. 
 
2. BACKGROUND 
2.1. Study Agent - Eribulin 
Eribulin mesylate  is a synthetic derivative  of the natural product halichondrin B , a large 
polyether macrolide isolated from a marine sponge ( Halichondria okadai ). Halichondrin B 
exhibits anti-cancer activity through a microtubule-destab ilizing anti-mitotic mechanism of 
action.1,2 Eribulin exerts its e ffects by [CONTACT_221815] e plus end of microtubul es, leading to tubulin 
sequestration into nonproductive ag gregates, preventing tubulin polymerization and microtubule 
dynamics. Suppression of microtub ule growth interferes with normal mitotic spi[INVESTIGATOR_221781], 
and blocks the prometaphase portion of mitosis,3 leading to irreversible  cell cycle blockade at 
G2/M, disruption of mitotic spi[INVESTIGATOR_36874], and cell death via apoptosis af ter prolonged mitotic 
blockage.[ADDRESS_266372], ovary, colon 
and melanoma.5 
The dosing regimen for eribulin selected ba sed on results of Phas e 1 studies is 1.4 mg/m2 
administered i.v. on Days 1 and 8 of a 3-week cy cle. In an early Phas e 2 trial, E7389-A001-201, 
the response rate (RR) in patients with breast cancer previously treated with anthracycline and 
taxanes was 11.5%. [ADDRESS_266373] chemotherapy regimen. The response rate for eribulin was 9.3% in these heavily pretreated 
subjects.
7 
In a Phase 3 trial, E7389-G000-305 (“EMBRACE”), eribulin (1.4 mg/m2 on Days 1 and 8 of a 3-
week cycle) was compared with treatment of  the physician’s choice (TPC; any cytotoxic or 
hormonal agent) in subjects heavily pre-treated for locally advanced or metastatic breast cancer 
(MBC). 8 In the analysis of the primary endpoint of overall survival, patients receiving eribulin 
had a longer median overall survival of 13.1 months compared with 10.7 months for TPC 
(P = 0.04, stratified log-rank test; hazard ratio = 0.81). Objective RR was 12% for eribulin 
mesylate and 5% for TPC ( P = 0.005). Grade 3 or 4 eribulin-related adverse events (AEs) 
included asthenia/fatigue (7.6%), neutropenia (44%), and peripheral neuropathy (8.4%). Twelve 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
10 
 percent of eribulin-treated subjects and 7% of TPC-treated subjects experienced treatment-
related serious AEs. Based on the results of this Phase [ADDRESS_266374] possible treatment advantages in 
comparison to other available agents for advanced disease (i.e. taxanes). Pr eclinical and clinical 
data suggest that eribulin mesylate may exhi bit less neurotoxicity, myalgia/arthralgia, and 
hypersensitivity than other chemotherapeutic ag ents. The most common AEs with single-agent 
eribulin mesylate are asthenia/fatigue and neut ropenia. In addition, eribulin requires minimal 
preparation, can be administered quickly, an d does not require premedication to prevent 
hypersensitivity. 
The current study will evaluate the safety and efficacy of eribulin for the treatment of HER2-
negative advanced breast cancer in the first- or second-line settings.  
2.2. Study Disease 
Breast carcinoma is the leading cause of cancer-rel ated mortality in women worldwide, with an 
estimated 1.[ADDRESS_266375] cancer 
were alive in 2004.10 Approximately 10% of patients with breast cancer have de novo metastatic 
disease from diagnosis, and another 10 to 20% present with locally advanced breast cancer. 
Additionally, up to one third of  patients with early stage breast cancer cases will develop 
metastatic disease in the course of their lives.[ADDRESS_266376] 30 years, however overall 
prognosis remains poor with a median survival of 2 to 3 years.12 Long term complete responses 
are observed only for a minority of MBC patients (2% to 5%), and MBC remains an incurable 
disease for most of patients.[ADDRESS_266377]-line chemotherapy ranges from 30% to 60%, with an 
associated time to progression (TTP) of [ADDRESS_266378]-line treatment is associated with a lo wer response rate (20% to 30%) and subsequent 
shorter TTP in the range of [ADDRESS_266379] cancer.  
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
11 
 2.3. Rationale for Correlative Studies – Patient Reported Outcomes 
When treating metastatic breast cancer, the du al goals of care are prolonging survival and 
optimizing QOL. Treatment selection requires cons ideration not only of potential anti-neoplastic 
activity, but also of possible toxi cities. Neuropathy is a common side  effect of many of the major 
chemotherapeutics with activity in MBC, in cluding taxanes, vinorelbine, ixabepi[INVESTIGATOR_54575], and 
eribulin. This toxicity is  of particular interest, as it can be  cumulative and, if severe, preclude 
further administration of potential active ther apy. Although ongoing studies will provide initial 
description of the activity of eribulin in less heavily pretreated patients, these trials are not 
designed to capture the full effect  of treatment on the patient as ide from response rate. In the 
present study, recommended instruments base d on the available evidence supporting their 
psychometric properties and past use in cancer research will be evaluated at baseline, during 
treatment and upon treatment completion.15  
Patient-reported outcomes (PRO) are an important part of new drug evaluation, and may play a 
role in regulatory approval of novel agents in oncology.16 PROs are the conse quences of disease 
and/or its treatment as reported by [CONTACT_25034]. PROs are evaluated through the use of 
questionnaires developed to assess topi[INVESTIGATOR_1102] a patient can report abou t his or her own health. This 
includes symptoms (i.e. nausea, fatigue, diarrh ea), physical functioning (difficulty climbing 
stairs or fastening buttons), and mental health (i.e. anxiety, fear or worry).  
Previous studies have demonstrat ed that patient and clinician re ports of symptoms during cancer 
treatment provide discrepant but complimentary information. 17-[ADDRESS_266380] 
mechanism for reporting toxicities  in cancer research is clinician-only reporting using items from 
the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE). In a retrospective an alysis of 14 randomized clinical  trials, PRO measures improved 
the predictive accuracy of clinician CTCAE reporting.20 In a prospective study including lung 
cancer patients PRO measurements of toxicities  better reflected patients’ underlying state and 
functional status than clinician’s evaluation.18 
In the current study, we will asse ss quality of life through validated questionnaires (FACT-B and 
FACT-Ntx) and the newly developed items of th e Patient-Reported Outcomes Version of the 
Common Terminology Criteria for Adverse Events (PRO-CTCAE).[ADDRESS_266381]-General 
(FACT-G) plus the Breast Cancer  Subscale (BCS), which adds items specific to QOL in breast 
cancer. Reliability and validity have been demonstrated in multiple patient samples. The Physical 
Well-Being (PWB), Functional Well-Being (FWB ) subscales are sensitive to change in 
performance status rating. Sensitivity to change has also b een demonstrated compared to the 
Functional Living Index-Cancer (F LIC) on the FACT-B total scor e, PWB, FWB, and Emotional 
Well-Being subscales. Internal consistency is high (alpha = 0.90) for th e total score, with 
subscale alpha ranging from 0.63 to 0.86. QOL an alyses using the Functional Assessment of 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266382] (FACT-B) have been presented from E2100, and are available as 
comparison data reflecting paclitaxel monotherapy.[ADDRESS_266383]-Neurotoxicity Subscale (FACT- Ntx) is aimed at the evaluati on of quality of life of cancer 
patients suffering from neurotoxicity. [ADDRESS_266384] between the National Cancer 
Institute (NCI) and clinical investigators with the intention that they will be available in future 
studies to allow patients to self-report their own adverse symptoms. The PRO-CTCAE item bank 
(i.e., lexicon of available questions) consists  of five “types” of item s (present/not present, 
frequency, severity, interference with usual or daily activities, and amount) which can be 
associated with any given symptom. The wordi ng and response options for each type of item are 
as follows (“XXXX” represents the given symptom):  
 
PRESENT/NOT PRESENT: In the last  [ADDRESS_266385] any XXXX: 
• Yes / No  
FREQUENCY: 
In the last [ADDRESS_266386] XXXX: 
• Never / Rarely / Occasionally / Frequently / Almost constantly 
 SEVERITY: 
In the last [ADDRESS_266387]: 
• None / Mild / Moderate / Severe / Very severe 
 INTERFERENCE: 
In the last 7 days, how much did XXXX INTERF ERE with your usual or daily activities: 
• Not at all / A little bit / Some what / Quite a bit / Very much 
 
AMOUNT: 
In the last [ADDRESS_266388] any XXX: 
• Not at all / A little bit / Some what / Quite a bit / Very much 
 For each symptom, the types of items used to a ssess the symptom were previously agreed in the 
development process of the National Cancer In stitute’s PRO-CTCAE project. For example, for 
the symptom of “pain”, the PRO-CTCAE includes three items: 
 
In the last [ADDRESS_266389] PAIN: 
• Never / Rarely / Occasionally / Frequently / Almost constantly 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266390]: 
• None / Mild / Moderate / Severe / Very severe 
 
In the last 7 days, how much did PAIN  INTERFERE with your usual or daily 
activities: • Not at all / A little bit / Some what / Quite a bit / Very much 
 Whereas, for the symptom of “shortness of breath”, the PRO-CTCAE includes only two items: 
 
 In the last [ADDRESS_266391]: 
• None / Mild / Moderate / Severe / Very severe 
 
In the last 7 days, how much did SHORTNES S OF BREATH INTERFERE with your usual or 
daily activities: • Not at all / A little bit / Some what / Quite a bit / Very much 
 and for the symptom of “constipation”, the PRO-CTCAE includes only one item: 
 In the last [ADDRESS_266392]: 
• None / Mild / Moderate / Severe / Very severe 
 
In total, the current version of the PRO-CTCA E has 126 items to assess 81 symptoms (Appendix 
6). There are 45 symptoms which are assessed us ing one item, 27 symptoms  which are assessed 
using two items, and 9 symptoms  which are assessed using three items. The types of items in 
order of prevalence include seve rity (used to assess 52 symptoms), frequency (used to assess 26 
symptoms), interference (used to assess 25 symp toms), present/not present (used to assess 
21symptoms), and amount (used to assess 2 symptoms).  There are 20 symptoms (39 items in total) which were identified as “core” symptoms by [CONTACT_169826]-CTCAE development team in  collaboration with NCI and FDA advisors based on their 
frequency in cancer patients and prior NCI tria ls, importance in monitoring, and/or inherent 
patient-reported nature. These symptoms include: Anxiety; arm or leg swelling; constipation; 
decreased appetite; loose or watery stools (diarrh ea); dry mouth; fatigue, tiredness, or lack of 
energy; hair loss; headache; insomnia; mouth or throat sores; nausea; numbness or tingling in 
your hands or feet; pain; problems with concentration; problems w ith tasting food or drink; rash; 
sad or unhappy feelings; shortn ess of breath; and vomiting. 
 
2.4. Rationale for Correlative Studies – Si ngle Nucleotide Polymorphisms and 
Neurotoxicity 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266393] only been described in heavily pretreated patients. In 
the EMBRACE study, with a median duration of drug exposure of 4 months, 8% of the 
pretreated population experi enced grade 3/[ADDRESS_266394] line weekly paclitaxel, the rate of grade 3/4 se nsory neuropathy was 18%, 
with a median duration of therapy of 5.[ADDRESS_266395]-line weekly paclitaxel, the rate of grade 3/4 sensory neuropathy was 16%.26 
Additionally, in RIBBON-2, which enro lled patients in the second li ne setting, the rate of grade 
3-4 sensory neuropathy was 13% in the chemot herapy alone arm (which included paclitaxel, 
gemcitabine, capecitabine, or vinorelbine).[ADDRESS_266396] factors, for example genetic polymorphisms that may be 
associated with neurotoxicity and other adverse effects. In the E2100 trial (paclitaxel 
chemotherapy backbone), genome wide associati on studies led by [INVESTIGATOR_124]. Bryan Schneider have 
identified 6 single nucleotide polymorphisms (SNP s) with minor allele frequency > 5% which 
were associated with neuropathy.[ADDRESS_266397] association wa s found for RWDD3, where the 
incidence of grade 2-4 neuropathy at any time point was 27% in homozygous wild-type patients versus 40% in heterozygous and 60% in homozygous variant patients. It would be of interest to 
explore whether the same SNPs are predictive of toxicity of other potentially neurotoxic agents. 
In addition, capturing neurotox icity with both traditional p hysician-rated CTCAE grading and 
with PROs may explore associations between host factors and toxicity in a more comprehensive 
fashion. 
In this study we will evaluate whether previo usly described SNPs are able to predict the 
observed neurotoxicity reported by [CONTACT_221816] a specific PRO a ssessment of neurotoxicity, but 
also physicians’ reported toxicity.  
 
2.5. Rationale for Study 
Eribulin has a well-demonstrated and approved role in the treatmen t of pretreated patients with 
metastatic HER2- breast cancer. In this se tting, the phase [ADDRESS_266398] 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
15 
 of eribulin on patient quality of life (QOL), compare toxicity evalua tion by [CONTACT_96553]-CTCAE versus 
provider-reported symptoms and validated QOL  surveys (FACT-B, FACT-Ntx), and provide 
samples for exploration of host polymorphisms on the development of chemotherapy-related 
toxicity. 
 
3. PARTICIPANT SELECTION 
3.1. Eligibility Criteria 
Subjects who meet all of the following crit eria may be included in this study: 
 Female or male age 18 years or older at the time of informed consent 
 Have histologically or cytologically proven invasive breast cancer, locally recurrent or 
metastatic, with at least one measurable le sion according to RECI ST v 1.1 (Appendix 1). 
Measurable disease is defined as: At least one lesion of [ADDRESS_266399] diameter 
for a non-lymph node or [ADDRESS_266400] or MRI 
 Patients may have hormone receptor positive or hormone receptor negative HER2-
negative disease. Hormone receptor positivity (ER and/or PR) is defined by [CONTACT_2669] 1% of 
positive tumor cells in the sample by [CONTACT_9064] (IHC). “Triple negative” is defined by [CONTACT_221817] n and progesterone re ceptor and by [CONTACT_94970]2-negative status. 
HER2-negative disease can be determined by [CONTACT_221818]. Negativit y by [CONTACT_221819] 0 or 1+. Borderline IHC re sults (i.e., 2+) should undergo FISH testing; 
subjects with an HER2 FISH ratio <
 2.0 are eligible. 
 Prior therapi[INVESTIGATOR_014] 
 Up to one prior line of chemotherapy for a dvanced disease is allowed. If received, 
prior chemotherapy must be discontinued at least 14 days prio r to initiation of 
protocol therapy. 
 Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable. 
 No limit on prior lines of endocrine th erapy or biologic therapy. Endocrine 
therapy and biologic thearpy must be discontinued at least 7 days prior to 
initiation of protocol therapy. 
 Patients must have completed any prior radiotherapy at least 2 weeks prior to 
initiation of protocol therapy. 
 Patients must have recovered from any reve rsible effects of prior therapi[INVESTIGATOR_221782] 1 toxicity, with the exception of alopecia. 
 ECOG PS score of 0, 1 or 2 (see Appendix 2) 
 Participants must have normal orga n and marrow function as defined below 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
16 
  Creatinine ≤1.5 mg/dL or calculate d creatinine clearance ≥40 mL/min per the 
Cockcroft and Gault formula (Appendix 3)  
 Absolute neutrophil count ≥1.5 x 109/L 
 Hemoglobin ≥ 9 g/dL  
 Platelet count ≥100 x 109/L 
 Bilirubin ≤1.5 times (x) the institutional ULN 
 ALT and AST ≤[ADDRESS_266401], or <  [ADDRESS_266402] in subjects with liver 
metastasis. 
 ECG QTC interval < 470ms  
 The effects of eribulin on th e developi[INVESTIGATOR_221783] e unknown. For this reason, 
women of child-bearing potential or men must agree to use adequate contraception (barrier 
method of birth control; abs tinence) prior to study entry a nd for the duration of study 
participation. Should a woma n become pregnant or susp ect she is pregnant while 
participating in this study,  she should inform her treating physician immediately. 
 
 Subjects willing and able to comply with all as pects of the protocol for the duration of the 
study and provide written informed consen t before any study-specific screening 
procedures are performed, with the understand ing that the subject may withdraw consent 
at any time without prejudice 
 
3.2. Exclusion Criteria 
Participants who exhibit any of the following conditions at screening will not be eligible  for 
admission into the study. 
 Prior treatment with eribulin 
 Subjects who have had a prior malignancy other than carcinoma in situ of the cervix or 
nonmelanoma skin cancer, unless the prior ma lignancy was diagnosed and definitively 
treated 1.5 or more years befo re enrollment in this study, with  no subsequent evidence of 
recurrence 
 Clinically significant cardiovascular impair ment (history of congestive heart failure 
greater or equal to NYHA Class II (Appendi x 4); unstable/active angina or MI ≤6 months 
before Day 1 of this study, or serious cardiac arrhythmia) 
 Active brain metastases or unevaluated neurologic symptoms suggestive of brain 
metastases. Subjects with brain metastasis and documented stable disease for > [ADDRESS_266403] ases will not be considered measureable 
lesions for the purposes of this trial. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
17 
  Subjects with metastatic diseas e limited to bone ar e ineligible unless at least one lytic 
lesion with identifiable soft tissue components that can be evaluated by [CONTACT_68454], that 
is measurable ( ≥15 mm at Baseline) and can be fo llowed serially by [CONTACT_393] v 1.1 
(Appendix 1).  
 Pulmonary lymphangitic involvement that resu lts in pulmonary dysfunction requiring the 
use of oxygen  
 Currently pregnant or breast-feeding. All fe males must have a negative serum or urine 
pregnancy test at the Baseline visit. Females of childbearing potential must agree to use a 
medically acceptable method of contraception (e .g., abstinence, an intrauterine device, a 
double-barrier method such as condom + sp ermicidal or condom + diaphragm with 
spermicidal, a contraceptive implant, an or al contraceptive or have a vasectomized 
partner with confirmed azoos permia) throughout the entire study period and for 30 days 
after discontinuation of study treatment. Subjects who will be exempt from this 
requirement are postmenopausal women (defined as women who have been amenorrheic 
for at least 12 consecutive months, in the a ppropriate age group, without other known or 
suspected primary cause) or subjects who have  been sterilized su rgically or who are 
otherwise proven sterile (i.e., bilateral tubal ligation, hysterectomy, or bilateral 
oopherectomy) 
 Subjects with organ allograft requiring immunosuppression 
 HIV-positive individuals on combination antiretroviral therapy are ineligible because 
of the potential for pharmacokinetic interactions with  eribulin. In addition, these 
individuals are at increased risk of lethal infections when treated with marrow-
suppressive therapy. Appropriate studies will be undertaken in participants receiving 
combination antiretroviral therapy when indicated 
 Subjects with pre-existing Gr ade [ADDRESS_266404] 
recover to Grade ≤1 before enrollment 
 Subjects with a hypersensitivity to halichondrin B or halichondrin B chemical derivative 
 Uncontrolled intercurrent illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, 
or psychiatric illness/social situations that would limit compliance with study 
requirements  
 Inability to read in English  
 
3.3. Inclusion of Minorities and Ot her Underrepresented Populations 
Both men and women are eligible for this protocol. Every effort will be made to include patients 
from minority populations. Because 
breast cancer pre dominantly affects female s, it is anticipated 
that male enrollment will be < 5% of the overall study population.  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
18 
  
4. REGISTRATION PROCEDURES  
4.1. General Guidelines for DF/H CC and DF/PCC Institutions 
Institutions will register eligible participants  with the DF/HCC Quality Assurance Office for 
Clinical Trials (QACT) central registration system. Registration must occur prior to the 
initiation of therapy. Any participant not registered to the protocol before treatment begins 
will be considered ineligible and registration will be denied.  
A member of the study team will confirm eligib ility criteria and complete the protocol-
specific eligibility checklist. Following registration, participants may begin pr otocol treatment. Issu es that would cause 
treatment delays should be discussed with the Overall Principal Investigator(PI). If a 
participant does not receive protocol therapy following registrati on, the participant’s registration 
on the study may be cancelled. Notify the QACT Regi strar of registration cancellation as soon 
as possible. 
4.2. Registration Process for DF/HCC and DF/PCC Institutions 
The QACT registration staff is accessible on Monday through Friday , from 8:00 AM to 5:[ADDRESS_266405] Time.  
 The registration procedures are as follows: 
1. Obtain written informed c onsent from the participant prior to the performance 
of any study related procedures or assessments. 
2. Complete the QACT protocol-specific e ligibility checklist using the eligibility 
assessment documented in the participant’s medical record and/or research 
chart. To be eligible for registration to  the protocol, the participant must 
meet all inclusion and excl usion criterion as descri bed in the protocol, and 
reflected on the eligibility checklist.  
 Reminder:  Confirm eligibility for ancillary studies at the same time as 
eligibility for the treatment study. Regist ration to both treatment and ancillary 
studies will not be completed if eligib ility requirements are not met for all 
studies. 
3. Fax the eligibility checklist(s) and all pages of the consent form(s) to the 
QACT at [PHONE_2095].  
4. The QACT Registrar will (a) review the eligibility checklist, (b) register the 
participant on the protocol, and (c) rando mize the participant when applicable.  
5. An email confirmation of the registrati on and/or randomization will be sent to 
the Overall PI, study coordinator(s) from the lead site, treating investigator 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
19 
 and registering person immediately following the registration and/or 
randomization. 
 
4.3. Registration Process for Other Investigative Sites 
 
To register a participant, the appropriate documents should be completed by [CONTACT_221820] [Fax [PHONE_4703]]  or e-mailed [[EMAIL_4377]]  to the 
Study Project Managers.  Please refer to Appendix 9: Section 3.7.[ADDRESS_266406] of appropriate documents. 
 The research nurse or data manager at the participating site will then e-mail [[EMAIL_4377]]  the Project Manager to verify eligibility.  To complete the 
registration process, th e Project Manager will 
 register the participant on the protocol with the QACT 
 fax or e-mail the participant study number, a nd if applicable the dose treatment level 
to the participating site 
 call the research nurse or data manager at the participating site and verbally confirm 
registration 
 
NOTE
: Registration and randomization with the QACT can only be conducted during 
the business hours of 8:00 AM and 5:[ADDRESS_266407] Time Monday through 
Friday. Same day treatment registrations wi ll only be accepted with prior notice and 
discussion with the DF/HCC Lead Institution. 
 
5. TREATMENT PLAN  
Treatment will be administered on an outpatient basis. Expected toxicities and potential risks as 
well as dose modifications for eribulin are de scribed in Section 6 (Expected Toxicities and 
Dosing Delays/Dose Modification). No investigational or commercial agents or therapi[INVESTIGATOR_221784]’s 
malignancy. 
 
5.1. Overall Study Design and Plan 
This is a non-randomized, open la bel study of eribulin monotherapy in the first or second line 
setting for metastatic HER2-negative breast ca ncer. Each subject will be assigned a unique 
identification number during screening, which will be used on all CRFs and correspondence 
regarding the subject. 
Patients receiving monotherapy will be  enrolled in 2 parallel cohorts: 
 Cohort 1: HR+/HER2-negative (n = 45 pts)  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
20 
  Cohort 2: TNBC (n= 45 pts) 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
21 
  
Treatment Description 
Agent Pre-medications Dose  Route Schedule Cycle 
Length 
Eribulin none 1.4 mg/m2  IV over 2 to 5 
minutes  Days 1, 8 
21 days 
(3 weeks) 
 
The starting dosage of eribulin mesylate in this study, 1.4 mg/m2 administered as an i.v. infusion 
over approximately 2 to 5 minutes on Days 1 and 8 of  a 3-week cycle, is ba sed on results of four 
Phase 1 and four Phase 2 clinical studies. Four  Phase 1 dose-finding studies were conducted to 
evaluate escalating doses of eribulin mesylate  and determine the maximum tolerated dose (MTD) 
of eribulin mesylate as: (1) a 1-hour i.v. infu sion on Days 1, 8 and 15 of a 28-day cycle (E7389-
A001-101); (2) a 1-hour i.v. infusi on on Day 1 of a 21-day cycl e (E7389-A001-102); (3) an i.v. 
bolus on Days 1, 8 and 15 of a 28-day cycle (N ational Cancer Institute [NCI] Study 5730); and 
(4) a bolus infusion on Days 1 and 8 of a 21-day cycle (E7389-J081-105). The MTD was 
determined to be 1.4 mg/m2 for the bolus inject ion and 1.0 to 2.0 mg/m2 for the infusion. 
Eribulin mesylate 1.4 mg/m2 i.v. bolus was tested as the starti ng dose in four Phase [ADDRESS_266408] two Phase 2 studies, subjects initially received eribulin mesylate  on Days 1, 8 and 15 in 
28-day cycles. Because the majority of subjects receiving the 28-day dosing schedule experienced dose delays, reductions, or omissions due to neutropeni a on Day 15 of the cycle, an 
additional cohort of subj ects who received eribulin mesylate 1.4mg/m
2 on Days 1 and 8 in 
21-day cycles was added. This schedule appeared to  be better tolerated than the 28-day schedule 
and demonstrated antitumor activity in all four Phase 2 studies. Thus, the optimal schedule of 
eribulin mesylate based on the four  studies appears to be 1.4 mg/m2 administered on Days 1 and 
8 in 21-day (3-week) cycles. 
 
5.2. Pretreatment Criteria 
Pretreatment criteria will be assessed within [ADDRESS_266409] demographic parameters include age, sex, and race/ethnicity (recorded in accordance 
with prevailing regulations). Baseline characteristics will  include ECOG PS (Appendix 2), 
NYHA cardiac disease classificatio n (Appendix 4), disease status, medical histories, prior and 
concomitant medications, and PE findings. Relevant hormone receptor status will be collected. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
22 
 Within the 21 days prior to therapy initiation patients will undergo baseline clinical evaluation 
(including history, physical evalua tion, vital signs, and performance status). Subsequent changes 
from screening PE findings that m eet the definition of an  AE will be recorded  on the AE page of 
the eCRF. 
Additional pre-treatment evaluations include: CBC with  differential, chemistries, pregnancy test (if 
indicated), tumor measurements by [CONTACT_221821], blood collection for co rrelative studies will occur at Cycle [ADDRESS_266410] dose of  administration of study treatment on Cycle 1, 
Day 1 and continue in 3-week (21-day) cycles. Subjects will continue to receive study treatment 
until the development of Progressi ve Disease (PD) or the subj ect meets another withdrawal 
criterion as described in Section 15. All s ubjects will receive eribulin mesylate 1.4 mg/m2 on Day [ADDRESS_266411] be 
discontinued; all enrolled subjects will then be treated according to prevailing local standards at the 
investigator's discretion. Subjects who discontin ue study therapy without PD will continue to 
undergo tumor response assessments every 9 weeks (from the date of the last tumor assessment) 
until PD is documented. All subjects will undergo an End-of-Treatment visit within 21 days after 
the final dose of study treatment.  
 
5.4. Agent Administration 
Eribulin Mesylate  
Eribulin mesylate 1.4 mg/m2 will be administered on an outpatient basis via i.v. infusion over 
approximately 2 to 5 minutes on Days 1 and 8 of each 3-week cycle. Therapy will continue until 
PD is documented or another withdrawal cr iterion is met as specified in Section 5.9.  All subjects 
will receive the same starting dosage of  eribulin mesylate, based on BSA.  
Please note that minor variations in treat ment dates (+/-3 days) may occur depending on 
physician and patient scheduling, observed holidays , inclement weather, etc. Regardless of the 
time of administration, toxicity from previous  treatment must be w ithin acceptable ranges as 
described below:  
Criteria for Eribulin administration 
 Absolute Neutrophil Count > 1,000/mm3 or >1.0×109/L 
 Platelet Count > 75,000/ mm3 or >75×109/L 
 Non-hematologic t oxicity CTCAE <  Grade 3 or 4 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266412] be 
calculated in the following manner: 
1. Scheduled dose (mg/m2) x body surface area (m2) = Dose (mg) 
2. Dose (mg) x 2 = the number of mL of eri bulin mesylate to withdraw from vials for 
administration 
Body surface area (BSA) will be calculated using any method that  is accepted and customarily 
used by [CONTACT_2727], such as the Mosteller formula: 
BSA (m2) = ([Height ([cm) x Weight (kg)]) ÷ 3600)½ 
Height and body weight will be reco rded at the screening visit. Thereafter, body weight will be 
recorded on each treatment day and dosing BSA will be calculated accordingly.  
The amount of eribulin mesylate required (as calculated above) will be  withdrawn from the 
appropriate number of vials into a syringe. This may be injected directly as an i.v. infusion over 
approximately 2 to 5 minutes or diluted in  up to 100 mL 0.9% saline for i.v. infusion over 
approximately 2 to 5 minutes. No special tubing is required for the i.v. admi nistration of eribulin 
mesylate. 
 
5.5. Schedule of Visits and Procedures 
5.5.1.  Pre-treatment phase  
Day -21 to Day 0  
Before performing any procedures or assessments, the investigator’s staff will explain the nature 
of the study and the potential risk s associated with the study to all subject candi dates and their 
respective partners where applicab le, and obtain written informed  consent from both if required. 
Once the IRB/IEC-approved ICF has been signed, th e following procedures and evaluations will 
be performed: 
 Determination of eligibility (inclu sion/exclusion criteria, Section 3): 
 Record demographic data 
 Evaluate ECOG PS score (must be 0, [ADDRESS_266413] to be eligible) (Appendix 
2) and cardiovascular status per NYHA criteria (Appendix 4)  
 Record medical and surgical history 
 Record all prior and concomitant medicat ion use (prescription and nonprescription 
medications as well as transfusions) beginning 30 days before the start of study treatment 
(except record all previous breast cancer treatments) 
 Perform physical examination 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
24 
  Obtain vital signs (BP, HR, respi[INVESTIGATOR_13521] y rate, and body temperature), weight, and 
height. 
 Perform tumor assessments to identify target  and nontarget lesions. Computed tomography 
or MRIs are to be obtained between Day -[ADDRESS_266414] 
one measurable lesion [ADDRESS_266415] diameter for a non-lymph node or 15 mm in 
the short-axis diameter for a lymph node 
 Obtain bone scan within 6 weeks be fore start of study treatment.  
 Perform a 12-lead ECG 
 Collect serum or urine sample for β-hCG pregnancy testing from all premenopausal and 
any postmenopausal women who have been amenorrheic for <12 months 
 Collect blood samples for clinic al chemistry and hematology an alyses (see Table 4) for a 
list of tests to be performed). 
 Collect blood samples for whole blood for germline DNA SNP analysis  
 Record any AEs (from the time of the first dose of study treatment) 
 Schedule Cycle 1 Day 1 Visit: Screening assessments may serve as baseline 
assessments if they are performed within [ADDRESS_266416] study visits on the day scheduled ( 3 days). The 
Study Calendar is provided in Table 3.  
Day 1 of Treatment  
 Record ECOG PS score (for Cycle 1: r ecord if not done at  Baseline visit) 
 Record weight (for Cycle 1: reco rd if not done at Baseline visit) 
 Record vital signs (BP, HR, respi[INVESTIGATOR_697] , body temperature) before administration of 
eribulin mesylate. 
 Perform one post baseline 12-l ead ECG on Day 1 of Cycle 2  before administration of 
study treatment 
 Perform physical exam  
 Collect blood samples for clinical chemistr y and hematology analyses within 3 days 
before the scheduled visit (see  Table [ADDRESS_266417] of tests to be performed). Laboratory 
assessments are not required on Day 1 of Cycle 1 if already performed at Baseline (within 3 
days before study administration) 
 Review all laboratory results befo re administering study treatment 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
25 
  Record all concomitant medication use 
 Cycle 1 D1, cycle 2 D1, cycle 3 D1, and ever y other cycle (i.e., cycles 5, 7, 9 until 
treatment discontinuation) -  Administer QOL surveys (F ACT-B, FACT-Ntx, and PRO-
CTCAE) and complete physicians re ported CTCAE as detailed below:  
 Administer the QOL surveys (FACT-B, FACT-Ntx, and PRO-CTCAE). Assessments 
may be performed within 3 days before the scheduled 
 Record selected provider-reported CTCAE (detailed in Table 3). Adverse events should 
be graded as the worst grade in the last [ADDRESS_266418] CTCAE 
grading which typi[INVESTIGATOR_221785]. Attempts should be made to ha ve provider-reported CTCAE and QOL surveys 
performed on the same day. 
 Administer study treatment: 
 Eribulin mesylate 1.4 mg/m2 as an i.v. infusion over approximately 2 to 5 
minutes 
 Record any AEs or SAEs 
Day 8 of Treatment  
 Record weight  
 Record vital signs (BP, HR, respi[INVESTIGATOR_13521] y rate, body temperature) before the 
administration of eribulin mesylate 
 Collect blood samples for hematology and chem istry analyses within 24 hours before the 
scheduled visit (see Table 4 for the tests to be performed).  
 Review all laboratory results befo re administering study treatment. 
 Administer study treatment: 
 Eribulin mesylate 1.4 mg/m2 as an i.v. infusion over approximately [ADDRESS_266419] dose of study treatment in  the next treatment cycle as indicated in the Study Calendar 
(Table 3): 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
26 
  Confirm Complete Response (CR) or Partial Response (PR) a minimu m of [ADDRESS_266420]/MRI at treatin g physician discretion. 
Scans can also occur as clin ically indicated for new symp toms or to confirm disease 
response. Radiological scans that were negative at baseline do not have to be repeated unless 
clinically indicated.  
End-of-Treatment Visit in the Treatment Phase  
Subjects will continue to receive study treatment until PD or anothe r withdrawal criterion is met, 
as described in Section 5.9. If a subject develo ps PD study treatment must be discontinued and 
end-of-treatment assessments be performed within [ADDRESS_266421] to be repeated if the same assessments 
were performed within 7 days of this visit. 
End-of-Treatment Visit  
 Perform tumor assessments as indicated in  the Study Calendar (Table 3). If study 
treatment is discontinued due to PD, then tumor assessments are not required for that subject. 
 Evaluate ECOG PS 
 Perform physical exam 
 Record vital signs (BP, HR, respi[INVESTIGATOR_13521] y rate, body temperature) and weight 
 Collect blood samples for hematology and seru m chemistry analyses (see Table [ADDRESS_266422] of tests to be performed) 
 Record all concomitant medication use. Concomitant medications should be collected 
for [ADDRESS_266423]  dose of study treatment. 
 End of treatment visit  - Administer QOL surveys (FACT-B, FACT-Ntx, and PRO-
CTCAE)and complete physicians reported CTCAE as detailed below:  
 Administer the QOL surveys (FACT-B,  FACT-Ntx, and PRO-CTCAE) survey. 
Assessments may be performed within 3 da ys before the scheduled clinic visit. 
 Record selected physicians reported CTCAE (detai led in table 2). Advers e events should be 
graded as the worst grade in the last [ADDRESS_266424] CTCAE 
grading which typi[INVESTIGATOR_221786] #: 13-077  
Version Date: 2/23/2016  
 
27 
 treatment. Physicians reported CTCAE and QO L surveys should be performed in the same 
day. 
 Record any AEs or SAEs 
All AEs, regardless of relationship to study treat ment or procedure or gr ade, will be collected 
from the time the subject signs the study ICF until [ADDRESS_266425]’s last 
study visit, whichever comes fi rst. However, treatment-emerg ent peripheral neuropathy and 
alopecia will be followed until resolution or another anticancer agent is started, whichever 
occurs first. Serious AEs will be collected for [ADDRESS_266426] treatment Follow-up Period (using the same methodology and 
acquisition techniques as were used  for previous assessments) every [ADDRESS_266427] tumor assessment until PD is documented (see the Study Calendar in Table 3. During the 
Follow-up Period, subjects who have treatment-em ergent peripheral neuropathy during the study 
will be followed until resolution of the neuropathy, or until another anticancer therapy is started, 
whichever occurs first. 
 
5.6. General Concomitant Medication and Supportive Care Guidelines 
All diagnostic, therapeutic, or surgical procedures re lating to malignancy s hould be recorded in 
the electronic case report form (eCRF), incl uding the date, indicatio n, description of the 
procedure(s), and any clinical findings. All previous treatments  for breast cancer should be 
included. 
All prior treatment or medication administered during the [ADDRESS_266428] be recorded on the Prior and 
Concomitant Therapy page of the eCRF. The ge neric name [CONTACT_18467] (or trade name [CONTACT_221861]) must be specified along with the duration of treatment and indication for 
use. If concomitant medication/therapy is administered for an adverse event (AE), investigators 
will record that AE on the AE page of the eCRF. 
Any medication that is considered necessary for th e subject’s welfare and that is not expected to 
interfere with the evaluation of study treatment may be give n at the discretion of the 
investigator. Ancillary treatments will  be given as medically indicated. 
Any changes in documented, permitted concomitant treatment already being taken at the start of 
the clinical study must be recorded on the eCRF , noting the type of medication, duration of use, 
and indication.  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
28 
 5.6.1.  Premedication  
Premedications (anti-emetics) ma y be administered before eribulin mesylate administration, but 
are not required. Premedication with steroids or antihistamines to prevent hypersensitivity 
reactions is not required. 
5.6.2.  Permitted concomitant Th erapi[INVESTIGATOR_221787], except as noted: 
 Antiemetics  
 Antidiarrheal therapy 
 Antiallergic measures such as corticosteroids and antihistamines 
 Granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), and erythropoie tin in accordance with American Society of 
Clinical Oncology guidelines a nd local standard practice.  
 Bisphosphonates: Subjects being treated with  bisphosphonates when they enter the study 
may continue the medication as long as the do se is stable. Subjects may also initiate 
bisphosphonate therapy while on protocol th erapy if it is thought to be medically 
necessary. 
 Palliative radiotherapy may be given for bone pain or for other reasons (i.e., bronchial 
obstruction, ulcerating skin lesi ons). The irradiated area s hould be limited and should not 
involve more than 10% of the bone marrow. Th e irradiated area cannot be used for tumor 
response assessment.  
 During palliative radiotherapy, treatment with  study treatment should be held. Treatment 
with study treatment may be resumed within [ADDRESS_266429] has recovered from any radiation-associat ed toxicity.  
 Ovarian suppression with goserelin or leuprolide are allowed on study. 
5.6.3.  Prohibited Concomitant Therapi[INVESTIGATOR_221788], other than eribulin mesylate is 
prohibited during this study. If subjects receive additional an titumor therapi[INVESTIGATOR_221789], hormone therapy (tamoxifen, arom atase inhibitors, fulvestrant), radiation 
therapy other than required for palliation, gene therapy, biologics , or immunotherapy, 
irrespective of the reason for which they are being given, this  will be judged to represent 
evidence of progressive disease (PD) and study treatment will be discontinued. These subjects 
will complete all end-of-treatment assessments. 
5.6.4.  Drug-Drug Interactions  
The weak inhibitory effect on cytochrome P450 enzymes exhibited by [CONTACT_221822] a low risk of eribulin mesylate intera ction with the pharmacokinetics of other drugs 
coadministered in usual clinic practice. Erib ulin mesylate exposure (area under the curve and 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
29 
 maximal concentration) was bioequivalent when ad ministered in combination with ketoconazole, 
a potent CYP3A4 inhibitor, compared with administration of eribulin mesylate alone. 
 
5.6.5.  Treatment Compliance  
Eribulin mesylate will be administered by [CONTACT_31610] d medical personnel at the investigational site. 
Treatment compliance will be monitored th rough documentation of study treatment 
administration in the subj ect’s medical record.  
 
5.7. Duration of Therapy 
Duration of therapy with eribul in will depend on individual response, evidence of disease 
progression and tole rance. In the absence of treatment de lays due to adverse events, treatment 
may continue until one of th e following criteria applies: 
 Development of progressive di sease by [CONTACT_221823] 
v 1.1 (Appendix 1) 
 Intercurrent illness that prevents further administration of treatment, 
 
 Unacceptable adverse event(s), 
 
 Participant demonstrates an inability or unwillingness to comply with the medication 
regimen and/or documentation requirements 
 
 Participant decides to withdraw from the study, or 
 
 General or specific changes in the participant's condition render the participant 
unacceptable for further treatment in the opi[INVESTIGATOR_80021] . 
 
5.8. Duration of Follow Up 
Participants will be followed for [ADDRESS_266430] may stop study treatment at any time for safety or personal reasons. 
Subjects who withdraw after signing the informed consent form (ICF) but before receiving study 
treatment will be replaced.  
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266431] be 
documented in the study-specific case report form (CRF). Alte rnative care options will be 
discussed with and, if necessary, provided for the participant. 
 
All subjects who withdraw from the study will be required to co mplete protocol-specified end-
of-treatment assessments within [ADDRESS_266432] dose of study treatment (end-of-treatment 
assessments will not have to be repeated if same assessments were done within [ADDRESS_266433] 
dose). Subjects who do not have progression u pon discontinuation of study treatment will have 
tumor assessments every [ADDRESS_266434] 
immediately notify the Principal Investigator  [INVESTIGATOR_193494] L. Mayer MD MPH at [PHONE_3401]. 
 
6. EXPECTED TOXICITIES AND DOSE/DELAYS MODIFICATION 
Dose delays and modifications will be made  using the following recommendations. Toxicity 
assessments will be done using the CTEP Active Version of the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) which is id entified and located on the CTEP website at: 
http://ctep.cancer.gov/protocolDevelopment/electroni c_applications/ctc.htm .  
 
If possible, symptoms should be managed sympto matically. In the case of toxicity, appropriate 
medical treatment should be used (includi ng anti-emetics, anti- diarrheals, etc.). 
 All adverse events experienced by [CONTACT_137453], through the study and until the fi nal study visit. Participants continuing to 
experience toxicity at the off study visit may be contact[CONTACT_221824]. 
 
6.1. Eribulin – Expected toxicities 
In a completed Phase 3 trial,  E7389-G000-305, eribulin (1.4 mg/m
2 on Days 1 and 8 of a 3-week 
cycle) was compared with treatment of the phys ician’s choice (TPC; any cytotoxic or hormonal 
agent) in subjects heavily pre-treated for locally advanced or metastatic breast cancer. Grade 3 or 
4 eribulin-related AEs were as thenia/fatigue (7.6%), neutr openia (44%), and peripheral 
neuropathy (8.4%). Twelve percent of eribulin-treated subjects a nd 7% of TPC-treated subjects 
experienced treatment-related SAEs. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
31 
 Refer to Section 5.2 of the Investigator's Brochur e for complete details on toxicity in previous 
clinical trials conduc ted with eribulin. 
6.2. Eribulin - Toxicity Management  
Subjects should be carefully mon itored for toxicity. If Grade 3 or  4 toxicities are present, then 
treatment should be delayed to allow for recovery (see instructions for dose delay below). If 
toxicities recur, the dose of eribulin should be re duced. In the setting of neutropenia, growth factor 
support may be added instead of a dose reduction at time of first occurrence of neutropenia at the 
discretion of the investigator. Once the dose of eribulin is reduced, it may not be increased at a 
later date. Dose adjustment recommendati ons for eribulin are shown in Table 1.  
Eribulin Dose Levels 
Starting dose 1.4 mg/m2 
1st dose reduction 1.1 mg/m2 
2nd dose reduction 0.7 mg/m2 
 
Table 1: Dose adjustment recommendations for eribulin  
 
Adverse reaction/Toxicitya Grade/Details Eribulin dose modification 
ANC < 500 cells/mm3 lasting > 7 days in 
the previous cycle without use of 
growth factors Hold eribulin until recovery to grade 
< 2. Eribulin may be resumed at the 
same dose with growth factor support, or it may be reduced by [CONTACT_30560], per investigator 
discretion. 
< 500 cells/mm3 lasting > 7 days in 
the previous cycle despi[INVESTIGATOR_221790] <
 2, and reduce by 1 dose level. 
<1000 /mm3 with  fever or infection 
without use of growth factors Hold eribulin until recovery to grade 
< 2. Eribulin may be resumed at the 
same dose with growth factor 
support, or it may be reduced by [CONTACT_23615], per investigator 
discretion. 
<1000 /mm3 with  fever or infection 
despi[INVESTIGATOR_221790] <
 2, and reduce by 1 dose level. 
<1000 /mm3 without  fever or 
infection without use of growth factors Hold eribulin until recovery to grade 
<
 2 then resume at the same dose 
with growth factor support.   
If uncomplicated neutropenia  lasting < 1 week (<1000 /mm3 
without fever or infection) 
occurs/recurs despi[INVESTIGATOR_61779], then hold eribulin until 
recovery to grade <
 2 . Eribulin may 
be then be resumed at the same dose 
with growth factor support, or it may 
be reduced by [CONTACT_30560], per 
investigator discretion. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
32 
  
If uncomplicated neutropenia  lasting > 1 week (<1000 /mm3 
without fever or infection) 
occurs/recurs despi[INVESTIGATOR_61779], then hold eribulin until 
recovery to grade <
 2 and reduce by 
1 dose level.  
  
Platelets Grade 2 Hold eribulin until recovery to grade 
1 
Grade 3 Hold eribulin until recovery to grade 
1 then reduce by 1 dose level. 
Grade 4 Hold eribulin until recovery to grade 
1 then reduce by 1 dose level. 
Anemia Grade 4 Hold eribulin until recovery to grade 
< 2 then reduce by 1 dose level. 
PRBC transfusions are permitted to 
treat anemia. 
 Peripheral neuropathy Grade 2 For intolerable (as determined by 
[CONTACT_221825]) grade 2, 
decrease chemotherapy by [CONTACT_37387].  
Grade 3 Hold eribulin until recovery to grade 
< [ADDRESS_266435] occurr ence Hold eribulin until recovery to grade 
< 2. Maximize supportive care 
measures.  If symptom recovery occurs within 1 week, then eribulin 
may be resumed at the same dose if deemed appropriate by [CONTACT_1275], otherwise, reduce by 1 
dose level. 
Recurrent grade 3, or any grade 4 toxicity Hold eribulin until recovery to grade <
 2 then reduce by 1 dose level. 
Recurrence of any Grade 3 or 4 event despi[INVESTIGATOR_197203] 0.7 mg/m2, or 
persistent grade 3 or 4 toxicity lasting more than 3 weeks despi[INVESTIGATOR_221791] = absolute neutrophil count 
a: Toxicities graded in accordance with National Cancer  Institute Common Toxicity Criteria for Adverse Events, 
version 4.0, Appendix 5 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
33 
  
 
Instructions for Dose Delay 
 
Criteria to continue treatment 
 Absolute Neutrophil Count >  1000/mm3 or >1.0×109/L 
 Platelet Count >  75,000/mm3 or >75×109/L 
 Non-hematologic toxicity <   grade 2 
 
Eribulin will NOT be administered if any of th e following values are present on Day 1 or 8 prior 
to treatment administration: 
 Absolute Neutrophil Count <1,000/mm3 or <1.0×109/L 
 Platelet Count <75,000/ mm3 or <75×109/L 
 Non-hematologic toxicity  CTCAE Grade 3 or 4 
 If the dose of eribulin cannot be administered as planned due to treatment-related toxicity, the 
dose should be delayed according to the following instructions: 
 Day 1 of each cycle: If eribulin cannot be administered on Day 1, the dose should be delayed 
until recovery to above mentioned values (crite ria for eribulin administration). The Day [ADDRESS_266436] to be reduced  following a dose delay in accordan ce to the instructions for dose 
reduction (Table 1). A maximum of 3 weeks are allowed for a delay in therapy. If the patient 
fails to meet the criteria to continue treatment within 3 weeks, they will be removed from the protocol. 
 
Day 8 of each cycle: If eribulin cannot be administered on Day 8, the dose should be delayed 
until recovery to above mentioned values (crite ria for eribulin administration). The Day 8 dose 
will be delayed for a maximum of 7 days and as follows: 
 
If the criteria for eribulin administration are me t on, or before Day 15 of a cycle, administer 
eribulin as recommended inTable 1; this dose is still called Day 8. 
 Eribulin administration on Day 1 of the next cycle should be no sooner than 14 days later. 
If the criteria for eribulin administration are NOT being met by [CONTACT_2006] 15 of a cycle, omit the 
Day 8 dose of eribulin for that cycle. Eribul in should be administered as recommended in 
Table 1 on Day 1 of the next scheduled cycle assuming criter ia to continue treatment are met 
within a maximum 3 week delay in ther apy from originally planned day 8. 
 
7. DRUG FORMULATION AND ADMINISTRATION  
7.1. Eribulin 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
34 
 Refer to the Investigator’s  Brochure for detailed ag ent information and Havalen® FDA 
approved package for more information. 
 
Description 
Chemical name:  11,15:18,21:24,28- Triepoxy-7,9-ethano -12,15-methano-9H,15H-furo[3,2-
i]furo[2',3':5,6]pyrano[4,3- b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-
hydroxypropyl]hexacosahydro- 3-methoxy-26-methyl-20,27-
bis(methylene)(2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29a
S)-, methanesulfonate (salt) 
Empi[INVESTIGATOR_62497]:  C40H59NO11•CH4O3S 
Molecular weight: 826.0 (729.9 for free base). 
Structural formula:  
 
  Other name: E7389, Halaven
® 
Mode of action: Eribulin injection is a non-taxane  microtubule dynamics inhibitor.  
Manufacturer: Eisai Molecular weight: 826.0 (729.9 for free base). 
Distribution: Vd: 43-114 L/m2 Protein binding:  49% to 65% 
Metabolism:  Negligible 
Half-life, elimination:  ~40 hours 
Excretion:  Feces (82%; predominantly as unchanged dr ug); urine (9%, primarily as unchanged 
drug) 
Form 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
35 
 Eribulin is clear, colorless, ster ile solution for intravenous admini stration. Each vial contains 1 
mg of eribulin as a 0.5 mg/mL solution in etha nol: water (5:95) .Eribulin is manufactured by 
[CONTACT_101382]. 
Storage and Stability  
Store undiluted eribulin in the syringe for up to 4 hours at room temperature or for up to 24 
hours under refrigeration (40°F or/ 4°C). Store diluted solutions  of eribulin for up to [ADDRESS_266437] unused portions of the vial. 
Compatibility 
Eribulin is compatible with saline (0.9% Sodium Chloride Injection). It is not compatible with 
solutions with dextrose. 
Handling  
Qualified personnel, familiar wi th procedures that minimize u ndue exposure to themselves and 
the environment, should undert ake the preparation, handling, and safe disposal of the 
chemotherapeutic agent in a self-con tained and protecti ve environment. 
Availability  
Eribulin is a commercially available agent but will be supplied free-o f-charge from Eisai.  
Preparation 
The amount of eribulin required wi ll be withdrawn from the appropr iate number of vials into a 
syringe. This may be injected directly as an i.v. infusion over approximately 2 to 5 minutes or 
diluted in up to 100 mL 0.9% saline for i.v. in fusion over approximately 2 to 5 minutes. Do not 
dilute in or administer through an intravenous line containing solutions with dextrose. Do not 
administer in the same intravenous line c oncurrent with the other medicinal products. 
Administration  
It will be administered over approximately 2-5 minutes. Do not administer in the same 
intravenous line concurrent with  the other medicinal products. 
Ordering 
Eribulin will be provided by [CONTACT_221826]. Under no 
circumstances will the investigator allow the study tr eatment(s) to be used other than as directed 
by [CONTACT_3181]. Clinical supplies will not be disp ensed to any individual who is not enrolled in 
the study. Please refer to Appendix 9: Section 4.[ADDRESS_266438] of the inventory and disposition of the agent (investigational or fr ee of charge) using the 
NCI Drug Accountability Record or anothe r comparable drug accountability form.  
Destruction and Return 
At the end of the study, unus ed supplies of eribulin should be destroyed according to 
institutional policies. Destruction will be do cumented in the Drug Accountability Record 
Form. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
36 
 8. CORRELATIVE STUDIES 
8.1. Patient-Reported Outcomes Assessment  
QOL surveys (PRO-CTCAE, FACT-B , FACT-Ntx) surveys will be administered at cycles 1, 2 
and 3, every other cycle in subseq uent cycles, and End-of-Treatme nt visit (detailed in Table 3 
and Appendix 6).  
In order to minimize incomplete data, which can be a major issue in survey research, surveys 
will be administered using electronic tablets at the specified study visits listed above. This will 
be performed via wireless tablet computers brought to patients by [CONTACT_464]. This is a well-
established method of administering electronic questi onnaires to patients. No data will be stored 
on these tablets, and data will be transmitted securely and in de-identified form in real-time to a server at the DFCI, where the data will be stor ed on highly secure servers. As a backup, paper 
copi[INVESTIGATOR_221792]. The PRO-CTCAE Software System will be 
used in this study to administer PRO-CTCAE items  to enrolled patients at designated clinic 
visits. Items of the PRO-CTCAE system defined as  core symptoms will be used in the present 
study (Appendix 6). 
If a participant is unable to fill out the survey us ing the electronic tablet, the survey may be filled 
out on paper with the patient ID , date, and timepoint clearly recorded. These paper surveys 
should be returned to the particip ating site, and a copy stored in th e patient research  record.   The 
original survey should be mailed to:Survey and Data Management Core 
RE: Eribulin Trial 
Dana-Farber Cancer Institute 
[ADDRESS_266439], LW 601 
[LOCATION_011], MA [ZIP_CODE] 
Selected provider-reported CTCAE (detailed in Ta ble 2, also attached as Appendix 8) will be 
collected on day 1 of cycles 1, 2 and 3, every other cycle in subse quent cycles, and off study visit 
for the purpose of assessing agreement between PRO-CTCAE and provider reported CTCAE. 
Data collection will occur using a form (Appendix  8) to be completed by [CONTACT_221827]. Adverse events will be graded as the worst grade in th e last [ADDRESS_266440] CTCAE grading which typi[INVESTIGATOR_221793]. This advers e event data collection is in addition to routine 
comprehensive adverse event reporting performed at  every encounter and de tailed in Table 3, the 
Study Calendar. 
 
Table 2:  Selected provider-reported CT CAE adverse events to be collected at cycles 1, 2 and 3, 
every other cycle in subsequent  cycles, and off study visit. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
37 
  
System Organ Class (SOC) Adverse event None Grade 1 Grade 2 Grade 3 Grade 4 
Gastrointestinal Disorders Constipation      
Diarrhea      
Dry mouth      
Mucositis      
N a u s e a       
Vomiting      
General disorders and 
administration site conditions Hair Loss    NA NA 
Edema limbs      
Fatigue      
P a i n       
Metabolism and nutrition disorders Anorexia      
Nervous system disorders Concentration impairment      
Dysgeusia      
Headache      
Peripheral sensory 
neuropathy      
Psychiatric disorders A n x i e t y       
Depression       
I n s o m n i a       
Respi[INVESTIGATOR_696], thoracic and 
mediastinal disorders Dyspnea      
 Abbreviations: Not applicable  
 
We expect that this study will provide supportive data as part of an accumulating body of 
evidence for the psychometric integrity of the PRO-CTCAE. 
8.2.  Correlative Neurotoxicity Analysis 
Previous analysis has identified single nucleo tide polymorphisms (SNPs) that predicted 
likelihood of experiencing taxane-induced peripher al neuropathy in the adjuvant breast cancer 
trial; E5103.29 In this study, we plan to explore whether these SNPs also predispose patients to 
peripheral neuropathy from eribulin.  
DNA sample preparation from whole blood 
Whole blood samples (10 ml) are collected in a tube  containing a standard anticoagulant, such as 
ACD, EDTA, or heparin. Samples are then stored in a -70°C freezer until they are ready to be 
shipped. The frozen blood samples are shipped on dry ice to Schneide r`s lab at Indiana 
University.  
The blood samples are thawed in a water bath at 37°C and gently agitated. Buffy coat samples 
are prepared by [CONTACT_221828]  3300 g for 10 minutes at room temperature and 
the intermediate clear layer of sample are collected for DNA extraction. QIAamp DNA Blood 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
38 
 Mini Kit is used to isolate DNA fr om the buffy coat samples. Step s in this process include lysis 
and digestion of the sample with a protease, a simple bind-wash-elute procedure, and finally 
precipi[INVESTIGATOR_221794]. 
Methods:  
DNA from buffy coat will be used to genotype candidate SNPs. The candidates will include 
those SNPs that had a provocative association with peripheral ne uropathy from prior work with 
paclitaxel in E5103. We will compare candidate  genotypes with the likelihood of developi[INVESTIGATOR_221795] l neuropathy in this trial. 
Shippi[INVESTIGATOR_221796]  
[ADDRESS_266441] Walther Hall C246 
Indianapolis, IN [ZIP_CODE] 
Tel: ([PHONE_4704] Fax: ([PHONE_4705] 
 
9. STUDY CALENDAR 
Table 3  summarizes the Study Calendar. Visits should occur within +/- [ADDRESS_266442] and determine the reason(s) for the missed visit as completely and 
accurately as possible. Subjects w ill only be judged as lost to fo llow-up if they cannot be reached 
after three documented attempts (1 week apart) by [CONTACT_221829].  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
39 
 Table 3: 
 Pre-Tx Treatment Phase (cycles 1 to 3 and subsequent 
cycles) End of tx. Follow-up 
Screening Cycle 1 Cycle 2 Cycle 3 Cycle 4 b   
Day(D) 
Assessments D –21 to 
D 0 D1 D8 D1 D8 D1 D8 D1 D8 Within 21 days of final dose 
c Every 9 weeks 
d 
I n f o r m e d  C o n s e n t  X            
Inclusion/Exclusion Criteria X            
D e m o g r a p h i c  D a t a  X            
ECOG PS X X  X  X  X  X  
Medical /  
Surgical History X            
Prior Medications / 
Procedures X            
Physical Examination X
e Xe  Xe  Xe  Xe  Xe  
Vital Signs Xf Xf Xf Xf Xf Xf Xf Xf Xf Xf  
Tumor Assessments Xa       Xa  Xa Xa 
12-Lead ECGg Xg   Xg        
Pregnancy Test  
(if applicable) Xh           
Hematology Xi Xi XiXiXiXiXiXiXiXi  
Blood Sampling  Xj          
Chemistry Xk Xk Xk Xk Xk Xk Xk Xk Xk Xk  
QOL assessments  Xl  Xl  Xl    Xl  
Eribulin mesylate   Xm Xm Xm Xm Xm Xm Xm Xm   
Concomitant 
Medications X X X X X X X X X X  
Adverse Events  Xn XnXnXnXn Xn
Provider CTCAE form  Xo  Xo  Xo    Xo  
 
 Footnotes 
Clinical chemistry and hematology anal yses screening assessment may serve as the baseline assessment if performed 
within 3 days (72 hours) before the first dose of study treatment. Assessments on Day 1 of each cycle may be performed 
within 3 days of administration of study treatment, except vital signs (which are measured before administration of 
eribulin mesylate).  
a:  Screening: Baseline tumor assessments of the chest, a bdomen, pelvis and other areas of known or newly suspected 
disease should be performed within [ADDRESS_266443] (Chest x-ray not 
permitted for tumor assessment). CT scans should be performe d with oral and iodinated i.v. contrast and MRI scans 
with i.v. gadolinium chelate unless there is a medical contraindication to contrast. If i.v. contrast is contraindicated, chest CT should be done without i.v. contrast. Skin lesions sh ould be clinically assessed using a metric ruler to calibrate 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
40 
 lesion size. A bone scan should be performed on all subjects within 6 weeks before start of treatment. 
Treatment Phase: Tumor assessments of the chest, abdomen and other areas of known disease that were scanned at 
Baseline, or newly suspected disease, must be performed every [ADDRESS_266444] dose of study treatment in the next treatment cycle, and should use 
the same methodology (CT/MRI) and scan acquisition techniques (including use or nonuse of i.v. contrast) as was used 
for the baseline assessments. Possible PR and CR (according to RECIST  v 1.1,Appendix ) must be confirmed at no less 
than [ADDRESS_266445] withdraws from the study for radiographic evidence of 
PD, tumor assessments are not required at the End-of-Treatment visit.  
Posttreatment Follow-up Period: Subjects without PD at the time study treatment is discontinued should have tumor 
assessments every [ADDRESS_266446] to be repeated unless clinically 
indicated.  
Bone Scans: Screening bone scans will be performe d within [ADDRESS_266447] to be repeated unless clinically 
indicated.  The same methodology and scan acquisition techniques used at screening should be used throughout the study.  
b:  Assessments in the subsequent treatment cycles should follow assessments specified in cycles 1 to 4. c: These assessments will also be conducted upon early discontinuation from the study. d: Subjects who discontinue study treatment without having PD  will return to the clinic for disease evaluation every 9 
weeks until PD is documented.  
e: Physical examination to be done at Sc reening, Day 1 of each cycle, and End-o f-Treatment visit. PE on Day 1 of each 
cycle may be done within 3 days before the scheduled visit. 
f: Height recorded at Screening. Weight  to be recorded on Days 1 and 8 of each  cycle and End of Treatment. Other vital 
signs (BP, HR, respi[INVESTIGATOR_697], and body temperature) will be recorded before administration of eribulin mesylate on 
Days 1 and 8 of each cycle.  
g: ECG evaluations will be performed for all subjects at Sc reening and during the Treatment Phase before starting the 
second cycle of eribulin mesylate (recommended to be on Day 1 of Cycle 2 before administration of eribulin mesylate).  
h:  Females of childbearing potential must undergo a urine or serum β-hCG pregnancy test at screening. 
i: Hematology will be measured on Day [ADDRESS_266448] be reviewed before 
administration of study treatment.  
j: Collection of whole blood for germline DNA and SNP analysis. If for any reason this sample is missed at baseline, or 
sample is insufficient; this may be redrawn at any timepoint  before participant is removed from the study. Refer to 
Appendix 7 for additional information.  
k: Serum chemistry parameters will be measured on Day [ADDRESS_266449] be reviewed before administration of study treatment. 
l: FACT-B, FACT-Ntx and PRO-CTCAE questionnaires to be recorded at Day 1 Cycles 1, 2 and 3, every other cycle in 
subsequent Cycles, and End-of-Treatment visit. Assessments may be performed within 3 days before the scheduled 
visit. 
m: Eribulin mesylate 1.4 mg/m2 given vi a i.v. infusion over 2 to 5 minutes on  Days 1 and 8 of each 3-week cycle. 
n: All AEs, regardless of relationship to study treatment or pr ocedure or grade, will be collected from the time the subject 
initiated therapy until [ADDRESS_266450]’s last study visit, whichever comes first. However, treatment-emergent peripheral neuropathy 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266451] treatment and followed until resolution or, if resolution is unlikely, until 
the event or sequelae stabilize. 
O: Adverse event assessments will be graded as the worst grade in  the last 7 days and recorded on Day 1 of Cycles 1, 2 and 
3, every other cycle in subsequent Cycles, and End-of-Treatment visit.. Complete form in Appendix 8. 
 
Abbreviations: BP = blood pressure; CBC = complete blood count; CNS = central nervous system; CR = complete 
response; CT = computed tomography; ECG = electrocardiogram; HR = heart rate; i.v. = intravenous; MRI = magnetic 
resonance imaging; PD = disease progression; PE = physical exam; PR = partial response; PS = performance status; QoL = 
quality of life; RECIST = Response Evaluation Criteria in Solid Tumors; Tx = treatment 
 
 
10. MEASUREMENT OF EFFECT 
10.1. Efficacy Assessments (Antitumor Activity) 
Tumor response assessments  
All tumor assessments will be performed and analyzed based on RECIST v 1.1 (refer to 
Appendix 1 for details). Eligible  subjects for this study must have measurable disease at 
Baseline, determined by [CONTACT_221830]. To assess best 
response (CR, PR, stable disease [SD], PD, not evaluable [NE]), each subject’s overall tumor 
burden at Baseline will be compared with subsequent measurements of lesions. Tumor response is to be assessed every [ADDRESS_266452] of 
radiographic evaluation (CT or MRI scans) of the chest, abdomen, pelvis, and any other areas of 
known or suspected disease, along with clinical a ssessment of skin lesions, if applicable, using a 
metric ruler in the field and m easured using calipers. A bone scan  should also be performed on 
all subjects within [ADDRESS_266453].  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
42 
 For subjects with a possible PR or CR (acco rding to RECIST v 1.1), changes in tumor 
measurements must be confirmed by [CONTACT_221831], to be performe d not less than [ADDRESS_266454] met. The same imaging modality and image-acquisition 
protocol (including use or nonuse of i.v. contrast) should be used across all time points to 
allow consistent comparison of lesions.  
The preferred type of CT scan  is a diagnostic quality spi[INVESTIGATOR_221797]-detector CT with i.v. and 
oral contrast. If iodinated i.v. contrast is contraindicated, it is recommended that the chest 
evaluation be done with noncontrast CT and the abdomen and pelvis evaluation be performed 
using either CT with oral contrast (without i.v.  contrast) or MRI with gadolinium chelate i.v. 
contrast. Low-dose noncontract CT transmissi on scans from a positron-emission tomography 
(PET)-CT combination scanner are not acceptable. Spi[INVESTIGATOR_23585]/multidetector CT and MRI body scans 
should be performed using ≤[ADDRESS_266455] (PET-CT) combination scanner are not acceptable methods of radiographic 
tumor assessment. However, a fluorodeoxygluc ose positron emission tomography (FDG-PET) 
scan, chest x-ray or skeletal x-ray that clearly demonstrates a new metast atic lesion may be used 
to document PD in lieu of the CT/MRI scans. 
Post screening bone scans  will be performed at treating phy sician discretion. Scans can also 
occur as clinically indicated for new symptoms  or to confirm disease response. Radiological 
scans that were negative at baseline do not have  to be repeated unless clinically indicated.  
The recommended bone scan technique is 99m-technetium-labeled methylene diphosphonate 
(99m-Tc-MDP) scintigraphy or w hole-body bone MRI. If an alternative scanning method is 
used, it should be continued thr oughout the rest of the study.  
The same methodology and scan acquisition t echniques used at screening should be used 
throughout the study to ensure comparability.  
A brain scan  by [CONTACT_221832]. Scans can 
also occur as clinically indicated  for new symptoms or to confir m disease response. Radiological 
scans that were negative at baseline do not have to be repeated unless clinically indicated. Brain 
scans should be performed with c ontrast-enhanced CT or MRI with ≤5-mm contiguous slices. 
Skin lesions should be clinically assesse d using a metric ruler in the field and measured using 
calipers. If subcutaneous masses or nodes are palpable (e.g., bulky) and are assessable by [CONTACT_221833], the radiographic (CT/MRI) technique should be used for 
the assessment of these lesions, whether target or nontarget. 
If study treatment is discontinued due to radiogra phic evidence of PD, the subject does not have 
to undergo tumor assessments at the End-of-Treat ment visit. Follow-up disease evaluation is not 
required for subjects who have radiographic eviden ce of PD at the time of discontinuation of 
treatment or for those subjects who w ithdraw consent before developi[INVESTIGATOR_4580]. 
10.2. Baseline Identification of Ta rget and Nontarget Lesions 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266456] up to a total of five measurable lesions (two per organ) 
that are representative of all involved organs as target lesions . Target lesions are to be selected 
on the basis of their size (the lesion with the longest diameter) and suitability for accurate 
repeated measurements (either by [CONTACT_221834]). To be considered a target 
lesion  at Baseline, the lesion must be meas urable and have a minimum size of [ADDRESS_266457] diameter for non- lymph node lesions or  15 mm in the short-axis for a lymph node. 
All other lesions (or sites of disease), both meas urable and nonmeasurable, will be identified as 
nontarget lesions  and will be recorded at Baseline. Nont arget lesions will be evaluated at the 
same assessment time points as target lesions. However, measurements will not be required, and 
these lesions will be followed as “present” or “absent.” 
Refer to Appendix 1 for further details on the evaluation of target a nd nontarget lesions. 
10.3. Primary efficacy variable/endpoint 
The antitumor activity of eribulin mesylate monotherapy will be assessed by [CONTACT_221835] v 1.1 (Appendix 1). For analysis purposes, ORR is defined as the proportion 
of subjects who achieve a CR plus those who achieve a PR. To be assigned a status of PR or CR, 
changes in tumor measurements must be confir med by [CONTACT_200967], to be performed not 
less than [ADDRESS_266458] response, duration of response 
and PFS, defined as follows: 
 Time to first response  will be defined for subjects whose best overall response (OR) is a 
CR or PR. The time to first response will be measured from the date of first dose of study treatment until the earli est date that CR or PR is objectively documented.  
 Duration of overall response
 will be defined for subjects  whose best OR is CR or PR. 
The duration of OR will be measured from th e time that response criteria for CR or PR 
(whichever is recorded first) are first met un til the date that PD or death from any cause 
is first objectively documented). Subjects w ho do not have PD will be censored on the 
day of their last tumor assessment. 
 Progression-free survival  will be defined as the time from the date of the first dose of 
study treatment until the date of first documen tation of PD or date of death from any 
cause (whichever occurs first). Subjects who die without reported PD are considered to 
have progressed on the day of their death. Subjects who are alive at the end of study 
without reported PD will be censored on the date of their last tumor assessment . 
10.5. Laboratory measurements 
Clinical laboratory tests will be performed at th e investigational sites. Screening assessments of 
laboratory parameters may be used as Baseline a ssessments if they are performed within 3 days 
before the start of study treatment.  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266459] be 
reviewed before administration of study treatment. 
The Study Calendar (Table 3) shows the visits at  which blood will be co llected for clinical 
laboratory tests.  
Hematology assessments  will be performed at Screening, Day 1 and Day 8 of each treatment 
cycle, and the End-of -Treatment visit.  
Clinical chemistry assessments  will be performed at Screening, Day 1 and Day 8 of each 
treatment cycle, and the End-of-Treatment visit. 
 
Table 4: Clinical Laboratory Tests 
Category Tests 
Hematologya  1. Hematocrit, hemoglobin, RBC, platel et count, WBC with differential 
(bands, basophils, eosinophils, lymphocytes, monocytes, neutrophils), 
ANC 
Clinical Chemistryb  
Screening/Baseline Panel 2. Pregnancy test (serum or urine β-hCG), chloride, potassium, sodium, 
BUN, serum creatinine, calcium, al bumin, total protein, alkaline 
phosphatase, ALT, AST, total bilirubin, magnesium 
Treatment Panel  3. Chloride, potassium, sodium, BUN, serum creatinine, calcium, 
albumin, total protein, alkaline phosphatase, ALT, AST, total bilirubin, 
magnesium 
ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; β-hCG = 
beta-human chorionic gonadotropin; BUN = blood urea nitrogen; RBC = red blood cells; WBC = white blood cells 
a: Hematology assessments obtaine d at Screening/Baseline, Days 1 and 8 of each treatment cycle  
b: Chemistry assessments obtained at Screening/Base line, and Day 1 and Day 8 of each treatment cycle  
 
10.6. Vital signs and weight measurements 
Vital sign measurements (blood pressure [BP], heart rate [HR], respi[INVESTIGATOR_697], oral body 
temperature [C]) and weight will be obt ained at the time point s designated on the Study 
Calendar. Height will be measured at the Screen ing Visit only. Weight will be recorded on Day [ADDRESS_266460] recei ves study treatment, for calculation of BSA.  
10.7. Electrocardiograms 
Standardized, 12-lead ECGs will be performed at  Screening, Baseline, once during Cycles 1 or 2 
(preferably on Day [ADDRESS_266461] ration of study treatment), and at the End-of-
Treatment visit. The Screening as sessment may be used as the Baseline assessment if the ECG is 
performed within 3 days before the start of study treatment.  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266462] fax the SAE report,  including the ECG repor t, to the Eisai Drug 
Safety Department using the SAE reporting form. 
 
11. ADVERSE EVENT REPORTING REQUIREMENTS 
 
11.1. Definitions 
11.1.1.  Adverse Event (AE)  
An adverse event (AE) is any undesirable sign, sy mptom or medical condition or experience that 
develops or worsens in severity  after starting the firs t dose of study treatment or any procedure 
specified in the protocol, even if the event is not considered  to be related to the study.  
 
Abnormal laboratory values or diagnostic test re sults constitute advers e events only if they 
induce clinical signs or symptoms or require  treatment or further diagnostic tests. 
 
11.1.2.  Serious adverse event (SAE)  
 
A serious adverse event (SAE) is any adverse ev ent, occurring at any dose and regardless of 
causality that:  
 Results in death 
 Is life-threatening. Life-threatening means that the person was at immediate risk 
of death from the reaction as it occurred, i.e., it does not include a reaction which 
hypothetically might have caused death had it occurred in a more severe form. 
 Requires or prolongs inpatient hospi[INVESTIGATOR_12191] (i.e., the event required at least a 
24-hour hospi[INVESTIGATOR_221798] a hospi[INVESTIGATOR_137406]). Hospi[INVESTIGATOR_6930]/or  surgical operations scheduled to occur 
during the study period, but planned prior to  study entry are not considered SAEs 
if the illness or disease existed before  the person was enrolled in the trial, 
provided that it did not dete riorate in an unexpected manner during the trial (e.g., 
surgery performed earlier than planned). 
 Results in persistent or significant disability/incapacity. Disability is defined as a 
substantial disruption of a person’s ab ility to conduct normal life functions. 
 Is a congenital anomaly or birth defect; or 
 Is an important medical event when, ba sed upon appropriate me dical judgment, it 
may jeopardize the participant and require medical  or surgical intervention to 
prevent one of the outcome s listed above. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home; blood dyscrasias or convul sions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of  drug dependency or drug abuse. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
46 
 Events not considered to be seri ous adverse events are hospi[INVESTIGATOR_5315]: 
 routine treatment or monito ring of the studied indicati on, not associated with any 
deterioration in condition, or for elective procedures 
 elective or pre-planned treatment for a pr e-existing condition that did not worsen 
 emergency outpatient treatment for an event not fulfilling the serious criteria 
outlined above and not resulting in inpatient admission 
 respi[INVESTIGATOR_4594] 
 
11.1.3.  Expectedness 
 
Adverse events can be 'Exp ected' or 'Unexpected.'  
Expected adverse event  
 
Expected adverse events are those that have been previously identif ied as resulting from 
administration of the agent. For the purposes of  this study, an adverse event is considered 
expected  when it appears in the current adverse event list, the Investigator’s Brochure, the 
package insert or is included in the info rmed consent document as a potential risk.    
 
Refer to Section 6.[ADDRESS_266463], the 
Investigator’s Brochure, the package insert or when it is not included in  the informed consent 
document as a potential risk. 
  11.1.4  Attribution 
 
Attribution is the rela tionship between an adverse event or  serious adverse event and the study 
treatment. Attribution will be assigned as follows: 
 
 Definite – The AE is clearly related  to the study treatment. 
 Probable – The AE is likely related  to the study treatment. 
 Possible – The AE may be related  to the study treatment.  
 Unlikely - The AE is doubtfully related  to the study treatment. 
 Unrelated - The AE is  clearly NOT related  to the study treatment. 
 
 
Procedures for AE and SAE Recording and Reporting  
Participating investigators will assess the o ccurrence of AEs and SAEs at all participant 
evaluation time points during the study.  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266464] or other means, will be recorded 
in the participant’s medical record and on the appropriate study-specifi c case report forms.  
 The descriptions and grading scales found in the revised NCI Common Te rminology Criteria for 
Adverse Events (CTCAE) version 4.[ADDRESS_266465] access to a copy of the CTCAE version 4.0. 
A copy of the CTCAE version 4.0 can be downloaded from the CTEP website at: 
 http://ctep.cancer.gov/protocolDevelopment/electroni c_applications/ctc.htm
. 
 
Reporting Requirements  
Each investigative site will be responsible to re port SAEs that occur at that institution to the 
Overall Primary Investigator , [CONTACT_221862] and to their own Institutional IRB. DF/HCC sites will report to [CONTACT_221862], and the DFCI/H CC IRB. Complete reporting instructions are 
described below.  
 
Reporting to the Study Sponsor  
Serious Adverse Event Reporting
 
 
Serious adverse events that occu r after the initial dos e of study treatment, during treatment, or 
within [ADDRESS_266466] be reported to the DF/HCC Overall Principal 
Investigator [INVESTIGATOR_141752]. This includes events meeting the following 
criteria:  
 Grade 2 (moderate) and Grade 3 (severe) Events – Only events that are 
unexpected and possibly, pr obably or definitely rela ted/associated with the 
intervention. 
  
 All Grade 4 (life-threatening or disa bling) Events – Unless expected AND 
specifically listed in the protoc ol as not requiring reporting. 
 
 All Grade 5 (fatal) Events – When th e participant is enrolled and actively 
participating in the trial OR when the even t occurs within [ADDRESS_266467] study 
intervention.  
 
Note
: If the participant is in long term fo llow up, report the deat h at the time of 
continuing review.  
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266468] report each serious adverse event to the DF/HCC Overall 
Principal Investigator [INVESTIGATOR_874] 24 business hours of learning of the occurrence. In the event that 
the participating investigator does not become aware of the serious a dverse event immediately 
(e.g., participant sought treatment el sewhere), the participating invest igator is to report the event 
within [ADDRESS_266469] awareness 
of the adverse event. Report serious adverse events by [CONTACT_756], email or facsimile to: 
 
  Erica L. Mayer, MD MPH 
  Telephone: [PHONE_3401] 
  Fax: [PHONE_3402] 
  [EMAIL_4378] 
 
Within the following 24-[ADDRESS_266470] provide follow-up 
information on the serious adverse event. Follo w-up information should describe whether the 
event has resolved or continues,  if and how the event was treat ed, and whether the participant 
will continue or discontinue study participation. 
Non-Serious Advers e Event Reporting  
 
Non-serious adverse events will be reported to the DF/HCC Overall Principal Investigator [INVESTIGATOR_221799].  
 
11.2. Reporting to the Institutional Review Board (IRB) 
 
Investigative sites within DF/HCC and DF/P CC will report SAEs directly to the DFCI 
Office for Human Research Studies (OHR S) per the DFCI IRB reporting policy.  
 
 
Other investigative sites will report SAEs to  their respective IRB according to the local 
IRB’s policies and procedures in reporti ng adverse events. A copy of the submitted 
institutional SAE form should be forwarded to the Overall PI [INVESTIGATOR_198016].   
 
 
 
 
Attribution DF/HCC Reportable AEs
Gr. 2 & 3 AE 
Expected Gr. 2 & 3 AE 
Unexpected Gr. 4 AE Expected Gr. 4 AE 
Unexpected Gr. 5 AE 
Expected or 
Unexpected 
Unrelated 
Unlikely Not required Not required 5 calendar days# 5 calendar days 24 hours* 
Possible 
Probable 
Definite  
Not required  
5 calendar days  
5 calendar days#  
5 calendar days  
24 hours* 
# If listed in protocol as expected and not requiring ex pedited reporting, event does not need to be reported. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
49 
 * For participants enrolled and actively participating in the study or for AEs occurring within [ADDRESS_266471] safety 
reports or sentinel events that require reporting according to institutional policy. 
 
11.4.  Reporting SAEs to EISAI 
All SAEs, as defined in Section 11.1.2, will be reported to EISAI on a Medwatch 3500A form 
within one business dayof the event. The reports will be sent to EISAI at the number listed 
below: 
 EISAI safety fax number ([PHONE_4706])  Email: [EMAIL_4379]  
 External participating sites will send Medwatch 3500A reports dire ctly to EISAI, and a copy will 
be sent to the DFCI project manager:  [EMAIL_4377]
 
 
DF/HCC sites will send the Medwatch 3500A reports directly to EISAI and file a copy in the 
study regulatory documents. 
 
11.5. Monitoring of Adverse Events and Period of Observation 
All adverse events, both serious and non-serious, and deaths that are encountered from initiation 
of study intervention, throughout the study, and with in [ADDRESS_266472] to follow-up. The presence and resolu tion of AEs and SAEs (w ith dates) should be 
documented on the appropriate case report form and recorded in the participant’s medical record 
to facilitate source data verification.  
 For some SAEs, the investigator or designee ma y follow-up by [CONTACT_756], fax, and/or monitoring 
visit to obtain additional case deta ils deemed necessary to appropr iately evaluate the SAE report 
(e.g., hospi[INVESTIGATOR_44458], consu ltant report, or autopsy report).  
 Participants should be instructed  to report any serious post-study event(s) that might reasonably 
be related to participa tion in this study. Participating investigators should  notify the DF/HCC 
Overall Principal Investigator [INVESTIGATOR_221800] #: 13-077  
Version Date: 2/23/[ADDRESS_266473], manage, and monitor data for this study.  
 
 Data Submission 
 
The schedule for completion and submission of case  report forms (paper or electronic) to the 
QACT is as follows: 
 
Form Submission Timeline 
Eligibility Checklist Complete prior to registration with QACT 
On Study Form Within approximately [ADDRESS_266474] day of 
the cycle 
Response Assessment Form Within approximately 10 days of the completion 
of the cycle required for response evaluation 
Off Treatment/Off Study Form Within approximately 14 days of completing treatment or being taken off study for any reason 
Follow up/Survival Form Within approximately 14 days of the protocol 
defined follow up visit date or call 
 
 
12.2. Safety Meetings 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
51 
 The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity 
and accrual data from this trial. The committee is composed of clinical specialists with 
experience in oncology and who have no direct re lationship with the study. Information that 
raises any questions about participant safety will be addressed with the Principal Investigator [INVESTIGATOR_16298].  
The DSMC will meet quarterly and/or more often if  required to review toxicity and accrual data. 
Information to be provided to the committee may include: up-to-da te participant accrual; current 
dose level information; DLT information; all grad e [ADDRESS_266475] been reported; summary of all deaths occurr ing within 30 days for Ph ase I or II protocols; 
for gene transfer protocols, summary of all d eaths while being treated and during active follow-
up; any response information; audit results, and a summary provided by [CONTACT_3476]. Other 
information (e.g. scans, laboratory va lues) will be provided upon request.   
 
12.3. Monitoring  
 
Involvement in this study as a participating investigator implies accepta nce of potential audits 
or inspections, including sour ce data verification, by [CONTACT_221836]/HCC 
Overall Principal Investigator [INVESTIGATOR_142985]/HCC. The pu rpose of these audits or inspections is to 
examine study-related activities and documents to determine whether these activities were 
conducted and data were recorded, analyzed, an d accurately reported in accordance with the 
protocol, institutional policy, and any applicab le regulatory requirements. Please refer to 
Appendix 9: Section 5.0 for additional information.  
 All data will be monitored for timeliness of  submission, completeness, and adherence to 
protocol requirements. Monitoring will begin at the time of participant registration and will 
continue during protocol pe rformance and completion.  
 
12.4. Multicenter Guidelines 
 
This protocol will adhere to the policies and re quirements of the DF/HCC Multi-Center Data and 
Safety Monitoring Plan.  The specific responsibilities of the Overa ll PI, Coordinating Center, and 
Participating Institutions a nd the procedures for auditing are presented in Appendix F
. 
 
The Overall PI/Coordinating Center is responsib le for distributing all IND Action Letters or 
Safety Reports to all participating institutions for submission to their individual IRBs for action 
as required.  
Mechanisms will be in place to ensure quality as surance, protocol compliance, and adverse event 
reporting at each site. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
52 
 Except in very unusual circumstances, each particip ating institution will order the study agent(s) 
directly from supplier.  A participating site may order the agent(s) only after the initial IRB 
approval for the site has been forw arded to the Coordinating Center. 
 
 
13. REGULATORY CONSIDERATIONS 
13.1. Protocol Review and Amendments 
This protocol, the proposed informed consent and all form s of participant information related 
to the study (e.g., ad vertisements used to recruit par ticipants) and any other necessary 
documents must be s ubmitted, reviewed an d approved by a proper ly constituted IRB 
governing each study location.  
Any changes made to the protocol must be su bmitted as amendments and must be approved 
by [CONTACT_221837]. Any changes in study conduct must be reported to the 
IRB. The DF/HCC Overall Principal Investig ator (or Protocol Ch air) will di sseminate 
protocol amendment information to all participating investigators.  All decisions of the IR B concerning the conduct of the st udy must be made in writing. 
 
13.2. Informed Consent 
All participants must be pr ovided a consent form descri bing this study and providing 
sufficient information for pa rticipants to make an informed decision about their 
participation in this study. The formal consent of a part icipant, using th e IRB approved 
consent form, must be obtained before the participant is involved in any study-related 
procedure. The consent form must be si gned and dated by [CONTACT_163901]’s legally authorized representative,  and by [CONTACT_98902]. The 
participant must be given a copy of the signed and dated c onsent document. The original 
signed copy of the consent document must be retain ed in the medical record or research file.  
 
13.3. Ethics 
This study is to be conducted according to the following considerat ions, which represent 
good and sound research practice: 
 US Code of Federal Regulations (CFR) governing clinical study conduct and 
ethical principles that have their or igin in the Declaration of Helsinki 
 Title 21 Part 50 – Prot ection of Human Subjects 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr50_02.html
  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
53 
  Title 21 Part 54 – Financial Disc losure by [CONTACT_98903].access.gpo.gov/nara/cfr/wai sidx_02/21cfr54_02.html   
 Title 21 Part 56 – Ins titutional Review Boards 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr56_02.html   
 State laws 
 DF/HCC research policies and procedures        
http://www.dfhcc.harvard.edu/clinical-research-support/clinical-research-unit-
cru/policies-and-procedures/   
 
It is understood that deviations  from the protocol should be avoi ded, except when necessary to 
eliminate an immediate hazard to a research participant. In such case, the devi ation must be 
reported to the IRB according to the local reporting policy. 
 
13.4. Study Documentation 
The investigator must prepare and maintain adeq uate and accurate case histories designed to 
record all observations and othe r data pertinent to the study for each research participant. This 
information enables the study to be fully docum ented and the study data to be subsequently 
verified.  
Original source documents supporting entries in th e case report forms include but are not limited 
to hospi[INVESTIGATOR_1097], c linical charts, laboratory and pharmacy  records, recorded data from 
automated instruments, microfiches, photographi c negatives, microfilm or magnetic media, 
and/or x-rays.   
13.5. Records Retention 
All study-related documents must  be retained for the maximum period required by [CONTACT_221838].  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266476] dose of (neo) adjuvant 
chemotherapy who enroll on protocol will be consider ed in the analysis as a second-line patient, 
even if no prior chemotherapy was re ceived in the metastatic setting. 
 
Demographic and Other Baseline Characteristics
 
Demographic and other baseline characteristics will be liste d, and summarized for the full 
analysis dataset. For continuous demographic/base line variables such as age, weight, and vital 
signs, results will be summarized and presented as number (N), mean, median, and range. For 
categorical variables such as race/ethnicity, the number and percentage of subjects will be used. 
Subject Disposition  
The number and percentage of subjects, who comp lete or prematurely withdraw from the study, 
as well as the reason for disc ontinuation, will be summarized.  
14.2. Determination of sample size 
The historical ORR data for chemotherapy in th e first-line metastatic setting indicated a 33% 
ORR for anthracycline and 38% ORR for taxanes. For patients  treated beyond first-line, the 
historical data indicate an appr oximate 20% ORR. This trial will be open for treatment in either 
the first- or second-line setting. The study primary endpoint is the ORR of eribulin given as 
monotherapy. ORR defined as th e proportion of subjects who ach ieve a confirmed CR or PR 
(RECIST 1.1), will be evaluated for each cohort separately using investigator-assessed data 
(Appendix 1). 
Statistical considerations for eribu lin monotherapy cohorts (cohort 1 and 2)  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
55 
 ORR will be estimated separately for the HR+/ HER2- and the TNBC mo notherapy cohorts. For 
the TNBC cohort, it is assumed there will be a 50-[ADDRESS_266477]- 
and second-line patients. The primary objective is to estimate the response rate (by [CONTACT_393] 1.1) to 
eribulin.  
From the meta-analysis of O’Shaughnessy et al, the ORR in TNBC in th e first-line setting was 
approximately 23%, and was 18% in the second-line setting based on the results of the TNBC 
subgroup of patients in the RIBBON -[ADDRESS_266478]- and second-line 
patients, we would assume a response rate of approximately 21-22% in th e cohort of TNBC.  For 
patients with HR-positive disease, the estimate d ORR from RIBBON-2 was 29.6% in the second-
line setting and has been reported to be between 33 -38% for first-line therapy.  We assume a 40-[ADDRESS_266479]- and second-line patient s in the HR-positive cohort, and conservatively 
estimate a response rate of 30% in this protocol. 
Our response rate assumptions for this protoc ol are 22% in the TNBC cohort and 30% in HR-
positive cohort. Because eribulin has already dem onstrated activity, including an overall survival 
advantage in the refractory setting, this study wi ll utilize a single-stage design. The sample sizes 
of each cohort were based on the lower bounds of the 90% exact confidence intervals (CI) 
around possible observed response rate s, as shown in the Table 5.  
Table 5: Eribulin Sample Size Table  
*Confidence intervals estimated using exact binomial methods. 
Sample 
Size (per 
cohort) Number 
responses Observed response 
rate Lower 
end 
90% CI* Upper end 
90% CI* Width 90% CI 
45 9 .200 .109 .323 .215 
11 .244 .144 .372 .228 
13 .289 .180 .420 .239 
14 .311 .199 .443 .244 
15 .333 .218 .466 .248 
16 .356 .237 .489 .252 
17 .378 .257 .511 .254 
18 .400 .277 .534 .257 
19 .422 .297 .555 .258 
20 .444 .317 .578 .261 
21 .467 .338 .599 .261 
For TNBC (orange) cohort, if [ADDRESS_266480] a response, then the lower bound of 
the 90% exact confidence in terval of the observed res ponse rate exceeds 22%.  
For ER+ (yellow) cohort , if [ADDRESS_266481]  a response, the lower bound of the 
90% exact confidence interval of the observed response rate exceeds 30%, which is the historical 
response rate of the combined 1st and 2nd line groups. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
56 
 In the TNBC cohort, there will be 90% power to detect a 22% percent improvement in response 
(22% vs. 44%) assuming an equal allocation of first-  and second-line pati ents.  In the HR-
positive cohort, there will be 90% power to dete ct a 23 percent improvement in response (30% 
vs. 53%) assuming first- and s econd-line patients ar e allocated approximately 40-60.  Both 
calculations assume a two-sided, 0.[ADDRESS_266482] one dose of  the study regimens will be included in the 
assessment of adverse events (full analysis pop ulation). Adverse event information for the two 
cohorts will be combined. Safety data that will  be evaluated include AEs, clinical laboratory 
results, vital signs, and ECGs. Abnormal laboratory values will be flagged.  
Adverse event information will be collected from the time the subject signs the ICF until 
resolution or for [ADDRESS_266483]’s last study visit, whichever come s first. Treatment-
emergent AEs (TEAEs) will be analyzed. Adverse events will be regarded as TEAEs if they 
started on or after the date and time of administ ration of the first dose of study treatment or if 
they were present before the ad ministration of the first dose of study treatment and increased in 
severity during the study. Treatment-emergent pe ripheral neuropathy w ill be followed until 
resolution or until the start of another anticancer th erapy post treatment, whichever occurs first.  
Adverse events will be graded using CTCAE v 4.0 (Appendix 5). Investig ators will collect all 
CTCAE grades for all AEs (to assess both increas ing and decreasing severi ty). Events will be 
summarized by [CONTACT_7237]. 
The incidence of TEAEs and relatedness to study treatment will be summarized. Although an 
adverse event may be reported more than once for a subject, that subject will be counted only 
one time in the incidence count for that advers e event term by [CONTACT_221839] (in the 
summary by [CONTACT_3229]) and by [CONTACT_221840] (in the 
summary by [CONTACT_221841]). 
14.4. Analysis of Secondary Efficacy Variables 
Progression-free survival (PFS) will be analyzed using Kaplan-Meier product-limit estimates and 
presented separately for each cohort. Median PFS and the cumulative probability of PFS at 6 and 
12 months will be presented with two side d 90% CIs derived using log(-log(survival)) 
methodology. Time to first response and duration of response will be summarized for the 
responders using the Kaplan-Meier method. The cumulative PFS, time to first response, and 
duration of response probabilities  will be plotted over time. Median and first and third quartiles 
from Kaplan-Meier estimation for PFS, time to fi rst response, and durati on of response will be 
provided with 90% CIs. 
14.5. Analysis of Quality of Life Assessments 
Patient reported outcome data will be combin ed for the monotherapy cohorts. QOL surveys 
(FACT-B, FACT-Ntx, and PRO-CTCAE) questionna ires will be obtained at baseline, C2D1, 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
57 
 C4D1, C7D1, and at the off-study visit. Quality of life (QoL) da ta will be combined for the 
monotherapy cohorts (Cohorts 1 and 2). 
 
FACT-B: At each assessment tim e, subscale scores for physic al well-being, emotional well-
being, social well-being, functiona l well-being, and relationship with  doctor will be scored per 
standardized scoring algorithms and will be pr esented individually and combined to obtain the 
FACT-G total score. In addition, the breast cance r subscale score will be summarized separately 
and combined with the FACT-G to obtain the summary score of the FACT-B. For all subscales 
and total scores, a higher score reflects better Qo L. Descriptive statistics will be presented for 
each subscale and total score. We will also summarize changes in scores between baseline and 
C2D1 to assess the effect of treatment upon QoL.  Change scores will be compared with zero 
using the Wilcoxon signed-rank test. For the combin ed monotherapy cohort, a sample of size [ADDRESS_266484] 80% power to detect a mean change  score that is 0.[ADDRESS_266485] 
deviation (i.e., effect si ze of 0.28), when tested at a two-sided 10% signifi cance level. Scores will 
also be summarized graphically over the repeat ed assessment times to derive a QoL response 
profile over the course of treatment.  
FACT-NTX: The effect of peripheral neuropa thy upon QoL will be summarized using the 11-
item FACT-NTX assessment. At each assessment tim e, scores will be summarized descriptively. 
Changes in score between baseline and C2D1 will also be summarized descriptively on a 
continuous scale, in addition to the proportion of patients who have c linically meaningful 
changes in score of 3 points or greater. The pr oportion will be presented with a 90% confidence 
interval estimated using exact bi nomial methods. For a sample of size 90, the conf idence interval 
will be no wider than 0.18.  
The primary purpose of the inclusion of PRO-CT CAE is to evaluate the performance of an 
electronic-based system for patient self-reporting of AEs, and assess whether PRO data 
collection improves the accuracy and description of each class of AEs. PRO-CTCAE data will 
also be compared with provide r-reported CTCAE toxicity data  to estimate the degree of 
concordance or divergence for each class of toxi city. The PRO-CTCAE data evaluation will also 
focus on accurate description of incidence and se verity of neuropathy in this patient population. 
The PRO-CTCAE data presentation and analysis w ill be descriptive and exploratory in nature.  
14.6. Neuropathy Analysis 
Comparison of candidate genotypes with the lik elihood of developi[INVESTIGATOR_221801]. 
 
15. PUBLICATION PLAN 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266486] Cancer 
Symposium. A full report of the outcomes will be made public no later than two (2) years after 
the end of data collection.   
Protocol #: 13-077  
Version Date: 2/23/2016  
 
59 
  
 
16. REFERENCES  
 
 1. Hirata Y, Uemura D: Halichondrins: ant itumor plyether macrolides from a marine 
sponge. Pure Appl Chem:701-10, 1986 
 2. Bai RL, Paull KD, Herald CL, et a l: Halichondrin B and homohalichondrin B, 
marine natural products binding in  the vinca domain of tubuli n. Discovery of tubulin-based 
mechanism of action by [CONTACT_221842] l cytotoxicity data. J Biol Chem 266:[ZIP_CODE]-9, 
1991  3. Jordan MA, Kamath K, Manna T, et al: The primary antimitotic mechanism of 
action of the synthetic halichond rin E7389 is suppression of mi crotubule growth. Mol Cancer 
Ther 4:1086-95, 2005 
 4. Kuznetsov G, Towle MJ, Cheng H, et al: Induction of morphological and 
biochemical apoptosis following prolonged mito tic blockage by [CONTACT_221843] B macrocyclic 
ketone analog E7389. Cancer Res 64:5760-6, 2004  5. Towle MJ, Salvato KA, Budrow J, et al: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogue s of halichondrin B. Cancer Res 61:1013-21, 2001 
 6. Vahdat LT, Pruitt B, Fabian CJ, et al: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane . J Clin Oncol 27:2954-61, 2009 
 7. Cortes J, Vahdat L, Blum JL, et a l: Phase II study of the halichondrin B analog 
eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, a nd capecitabine. J Clin Oncol 28:3922-8, 2010 
 8. Cortes J, O'Shaughnessy J, Loesch D, et al: Eribulin monotherapy versus 
treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 
open-label randomised study. Lancet 377:914-23, 2011  9. Jem al A, Bray F, Center MM, et al: Gl obal cancer statistics. CA Cancer J Clin 
61:69-90, [ADDRESS_266487]-Marty C, Cardoso F, Pi[INVESTIGATOR_191039]: Facts and controversies in systemic 
treatment of metastatic breast cancer. Oncologist 9:617-32, 2004 
 12. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic 
complete remission rate after neoadjuvant thera py with trastuzumab, paclitaxel, and epi[INVESTIGATOR_221802]: results of a randomized trial in  human epi[INVESTIGATOR_3506] 2-
positive operable breast cancer. J Clin Oncol 23:3676-85, 2005  13. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J 
Clin Oncol 14:2197-205, [ADDRESS_266488] C, Rissanen P, et al: Salvage therapi[INVESTIGATOR_221803]-line treatment with fluorouracil , epi[INVESTIGATOR_14962], and cyclopho sphamide for advanced 
breast cancer. J Clin Oncol 12:1639-47, 1994  15. Dueck AC, Mendoza TR, Mitchell SA, et al: Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-
CTCAE). J Clin Oncol 30:9047, 2012 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
60 
  16. Rock EP, Kennedy DL, Furness MH, et al: Patient-reported outcomes supporting 
anticancer product approvals. J Clin Oncol 25:5094-9, 2007 
 17. Fromme EK, Eilers KM, Mori M, et al: How accurate is clinician reporting of chemotherapy adverse effects? A comparison with  patient-reported symptoms from the Quality-
of-Life Questionnaire C30. J Clin Oncol 22:3485-90, 2004  18. Basch E, Jia X, Heller G, et al: Ad verse symptom event reporting by [CONTACT_221844]: relationships with clinical outcomes. J Natl Cancer Inst 101:1624-32, 2009 
 19. Petersen MA, Larsen H, Pedersen L, et  al: Assessing health-re lated quality of life 
in palliative care: comparing patient and phys ician assessments. Eur J Cancer 42:1159-66, 2006 
 20. Quinten C, Maringwa J, Gotay CC, et al: Patient self-reports of symptoms and 
clinician ratings as pr edictors of overall cancer survival . J Natl Cancer Inst 103:1851-8, 2011 
 21. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality -of-life instrument. J Clin Oncol 15:974-86, 1997 
 22. Cella D, Wang M, Wagner L, et al: Surviv al-adjusted health-related quality of life 
(HRQL) among patients with metastatic breast cancer receiving paclita xel plus bevacizumab 
versus paclitaxel alone: results from Ea stern Cooperative Oncology Group Study 2100 (E2100). 
Breast Cancer Res Treat, 2011  23. Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the 
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 
(Fact/GOG-Ntx) questionnaire for patients recei ving systemic chemotherapy. Int J Gynecol 
Cancer 13:741-8, 2003  24. Wozniak KM, Nomoto K, Lapi[INVESTIGATOR_182175], et al: Comparison of neuropathy-inducing 
effects of eribulin mesylate, paclitaxel, a nd ixabepi[INVESTIGATOR_221804]. Cancer Res 71:3952-62, 2011 
 25. Amir E, Miller N, Geddie W, et al: Prospective study evaluating the impact of 
tissue confirmation of metastatic disease in patients with br east cancer. J Clin Oncol 30:587-92, 
2012 
 26. Rugo HS, Barry WT, Moreno-Aspi[INVESTIGATOR_54604] A, et al: CALGB [ZIP_CODE]/NCCTG N063H: 
Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin 
bound nab-paclitaxel (NP) or ixabepi[INVESTIGATOR_54575] (Ix) w ith or without bevacizu mab (B) as first-line 
therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30:CRA1002, 2012 
 27. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of 
cardiac function in NSABP B-31, a random ized trial comparing doxorubicin and 
cyclophosphamide followed by [CONTACT_221845] (ACP) with ACP plus tras tuzumab as adjuvant therapy 
for patients with node-positive, human epi[INVESTIGATOR_221805] 2-positive breast cancer. 
J Clin Oncol 30:3792-9, 2012 
 28. Schneider B, Li L, Miller K, et a l: Genetic associations  with taxane-induced 
neuropathy by a genome-wide a ssociation study (GWAS) in  E5103. J Clin Oncol 29:A1000, 
2011  29. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial 
growth factor and vascular e ndothelial growth factor recepto r-[ADDRESS_266489] 
cancer: ECOG 2100. J Clin Oncol 26:4672-8, 2008  
 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266490] v 1.1 based on the 2009 article by 
[CONTACT_221846]. entitled, New response evaluation criteria in so lid tumours: Revised RECIST guideline 
(version 1.1) .Error! Bookmark not defined.  This Appendix contains an overview of the RECIST v 1.1 
guidelines. For complete details, the Eisenhauer article, published in the European Journal of Cancer , 
is available online at: http://linkinghu b.elsevier.com/retrie ve/pii/S0959804908008733 . 
Baseline Tumor Assessment 
Subjects are required to have measurable disease, defined as the presence of at least one measurable 
lesion, to be eligible for entry into the study. Measurable and nonmeasurable lesions are defined as: 
 Measurable lesions : Lesions that can be accurately measured in at least one dimension (longest 
diameter [LD] to be recorded) with a minimum size of >[ADDRESS_266491] (CT slice thickness 
of ≤5 mm; for slice thicknesses >[ADDRESS_266492] diameter ≥2 
times the slice thickness) or caliper measurement by [CONTACT_461]. A lymph node
 will be considered pathologically enlarged and measurable if its short axis is ≥15 
mm; the short axis should be measured and followed throughout. Nodes with a short axis ≥ 10 mm 
and <15 mm will be considered pathologically enlarged but nonmeasurable. 
Lytic bone lesions  or mixed lytic-blastic lesions  with identifiable soft-tissue components will be 
considered measurable if the soft-tissue component can be evaluated by [CONTACT_12783]-sectional imaging (i.e., CT scan) and meets the general definitio n of measurability. Blastic bone lesions are 
nonmeasurable. 
A lesion located in a previously irradiated area
, or in an area previously subjected to any 
locoregional therapy, will be considered measurab le only if there has b een a documented increase 
in lesion size subsequent to prior treatment but before study entry. 
Clinical lesions  will only be considered measurable when they are superficial (e.g., skin nodules) 
and should be assessed using a metric ruler to est imate the size of the lesion. The minimum lesion 
size is ≥10 mm. 
 Nonmeasurable lesions : All other lesions, including small lesions (LD <10 mm or pathological 
lymph nodes with a short axis of ≥10 mm to <15 mm), lesions that cannot be accurately measured 
with calipers, and truly nonmeasurable lesions: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses/abdominal organomegaly identified by [CONTACT_87415]. Lymph nod es with a short axis <10 mm are considered 
nonpathological and should not be recorded or followed. Simple cysts
 (cystic lesions) will not be considered malignant, and will be neither measurable nor 
nonmeasurable. Cystic lesions believed to be me tastases may be considered measurable if they 
meet the general definition of measurability, but no ncystic lesions are preferred as target lesions. 
Baseline evaluations should be performed as closely as possible to the start of treatment and within [ADDRESS_266493] dose of study treatment (bone scans should be performed within 6 weeks of start of 
treatment).  
Methods of Tumor Measurement 
The same imaging modality and the same technique (including use or nonuse of oral and i.v. contrast) 
should be used to characterize each identified and reported lesion at Baseline/Screening and at 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266494] currently available and reproducible methods to measure 
target lesions selected for response assessment. Comput ed tomography should be performed with slices of 
5 mm or less in thickness (as a general rule, lesion diameter should be no less than double the slice 
thickness). This applies to tumors of the chest, abdomen, and pelvis. Magnetic resonance imaging is also 
acceptable in certain conditions (e.g., for body scans). A CT  of the chest without contrast is preferred over 
MRI. Bone scans, positron emission tomography (PET) scan, or plain films
 are not sufficient to measure bone 
lesions and document objective response, but may be  used to confirm the presence or disappearance of 
such lesions. Bone scans  should be performed using 99m -technetium-labeled polyphosphonate 
scintigraphy. 
Chest x-rays  should not be used for baseline assessment of  the chest or for follow-up of known lesions. 
Chest CT should be used. Ultrasound
 should not be used to measure tumor lesions. 
Endoscopy and laparoscopy  should not be used to measure tumo r lesions. However, such techniques can 
be useful in confirming complete pat hological response or determine relapse. 
Tumor markers  alone cannot be used to assess response. If markers are initially above the upper normal 
limit, they must normalize for a subject to be consid ered in complete clinical response when all lesions 
have disappeared.  
Cytology and histology  can be used to differentiate between PR and CR in rare cases (e.g., after treatment 
to differentiate between residual benign lesions an d residual malignant lesions in tumor types such as 
germ cell tumors). Documentation of “Target” and “Nontarget” Lesions 
Lesions are evaluated and classified at Baseline as either target or nontarget and all are then followed 
throughout the study. 
Target Lesions: 
Target lesions are all measurable lesions up to a ma ximum of two lesions per or gan and five lesions in 
total, representative of all involved organs. Target lesions should be selected on the basis of their size 
(those with the longest diameters) and their suitability for accurate repeated measurements. 
The short axis ( ≥15 mm) of any lymph nodes selected as target lesions at Baseline will be measured and 
recorded at each evaluation time point, even if the nodes become nonpathological (short axis <10 mm). The sum of the diameters of all target lesions (longest for non-nodal lesions, short axis for nodal lesions) 
will be calculated at Baseline and reported as the ba seline sum diameter. This baseline sum diameter will 
be used as the reference by [CONTACT_221847]. For lesions measurable in two 
or three dimensions, the LD must be reported at the time of each assessment. Target Lesions Too Small To Measure : 
Lesions that become too small to measure during tr eatment should be assigned a default measurement of 
either 0 mm (if the investigator believes the lesion h as disappeared) or 5 mm (if the lesion is believed to 
be present and is faintly visible). Target Lesions That Split or Coalesce : 
If a non-nodal target lesion fragments during treatment, the longest diameters of each fragment should be 
added together to calculate the total sum for that lesion. When lesions coalesce, a plane between them 
may be maintained that would aid in obtaining maximal diameter measurements for each individual 
lesion. If the lesions are no longer separable, the vector of the longest diameter in this instance should be 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266495] diameter for the coalesced lesion. 
Nontarget Lesions: 
All other lesions (or sites of disease) should be identified as nontarget lesions and should also be 
recorded at Baseline. Measurements of these lesions are not required, but the presence or absence of each 
should be noted throughout Follow-up. New Lesions : 
The finding of a new lesion should be unequivocal (i.e., not attributable to a change in scanning technique 
or imaging modality, and not though t to represent something other than a tumor). If a possible new lesion 
is equivocal, treatment and radiogra phic evaluation should continue per this protocol until confirmation of 
PD or until additional scans confirm the presence of a new lesion. In such a case, the date of progression 
will be the date of the initial scan. 
A lesion identified on a Follow-up study of an anatomical location not studied as Baseline will
 be 
considered a new lesion. Scanning with FDG-PET may be employed as a comple ment to CT scanning in the assessment of PD. A 
negative FDG-PET scan at Baseline with  a positive scan during the study will be evidence of PD. If there 
is no FDG-PET scan at Baseline and a positive FDG-PET scan during the study, it will be considered 
evidence of PD if the positive FDG-PET corresponds to a new site of disease confirmed by [CONTACT_3610]. A 
positive postbaseline FDG-PET result corresponding to a pre-existing site of disease with no radiographic 
evidence of progression will not be considered evidence of PD. Evaluation of Response for an Individual Assessment Time Point 
To determine tumor response, the sum of all target lesions is calculated at Baseline and at each subsequent assessment time point (i.e., every 9 weeks) . Each response parameter (target, nontarget, and 
new lesions) will be reported independently at each ra diographic reading as shown in Table 1 for target 
lesions and Table 2 for nontarget lesions. The investigator will then make a determination of OR for each 
assessment time point based on a composite evaluation of target, nontarget, and new lesions, as shown in 
Table 3.  
 
Table 1 Evaluation of Target Lesions  
Complete Response (CR) Disappearance of al l target lesions. All pathological lymph nodes 
(whether target or nontarget) must  have a reduction in their short 
axis to <10 mm. 
Partial Response (PR) At least a 30% decrease in the sum of the LD of target lesions, 
taking as reference the Baseline sum diameters 
Progressive Disease (PD)  At least a 20% increas e in the sum of the LD of target lesions, 
taking as reference the smallest  sum LD recorded at Baseline or 
during treatment. The sum must also  have an absolute increase of 
≥5 mm. The appearance of one or more new lesions is also 
considered PD. 
Stable Disease (SD) Neither sufficient shrinkage  to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest  sum LD since the 
treatment started 
Not Evaluable (NE) or Unevaluable No imaging/measurement done at all or only on a subset of lesions at a particular time point; a target lesion at Baseline which is 
subsequently not measured or  which is unable to be 
evaluatedIncludes scans that are not  performed at a specified time 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
64 
 point to evaluate the target lesion(s).  
 
Table 2 Evaluation of Nontarget Lesions 
Complete Response (CR) Disappearance of all nontarget lesions; normalization of tumor 
marker level. All lymph nodes <10 mm (short axis) 
Non-CR/Non-PD Persistence of one or more  nontarget lesion(s) and/or maintenance 
of tumor marker level above the normal limits 
Progressive Disease (PD) Unequivocal progression (substantial worsening in nontarget 
disease such that overall tumor burde n has increased sufficiently to 
warrant discontinuation of therapy); appearance of one or more new 
lesions and/or unequivocal progression of existing nontarget 
lesionsa 
Not Evaluable (NE) A nontarget lesion at Base line which is subsequently not measured 
or which is unable to be evaluated 
a. Although a clear progression of “non target” lesions only is exceptional, in such circumstances, 
the opi[INVESTIGATOR_3525]. 
 
Table 3  Overall Response at Each Assessment Time  Point for Subjects with Target (+/- 
Nontarget) Disease 
Target Lesions Nontarget Lesions New Lesions Overall Response 
CR CR No CR 
CR Non-CR/Non-PD No PR 
CR Not evaluated No PR 
PR Non-PD or not all evaluated No PR 
SD Non-PD or not all evaluated No SD 
Not all evaluated Non-PD No NE 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
CR = complete response; NE = not evaluable; PD = disease progression; PR = partial response; SD = 
stable disease 
 
 Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of PD at that time point assessment should be classified as having “symptomatic deterioration.” Every effort s hould be made to document objective progression 
after discontinuation of treatment. 
 In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of CR depends on this determ ination, it is recommended that the residual 
lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) before assigning a status of CR. 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266496] response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for PD th e smallest measurements recorded since the 
treatment started). In general, the subject's best response assignment will depend on the achievement of 
both measurement and confirmation criteria as shown in Table 4. 
Confirmation: To be assigned a status of PR or CR, changes in tumor measurements must be confirmed 
by [CONTACT_221848] l ess than [ADDRESS_266497]/MRI  are performed at treating physician discretion. Scans 
can also occur as clinically indicated for new symp toms or to confirm disease response. Radiological 
scans that were negative at baseline do not have  to be repeated unless clinically indicated.  
 
 The main goal of confirmation of the PR or CR objective response is to avoid overestimating the 
response rate. In cases where confirmation of r esponse is not feasible, it should be made clear 
when reporting the outcome that the response(s) are not confirmed. 
 In the case of SD, follow-up measurements must have met the SD criteria at least once after 
study entry at a minimum interval of [ADDRESS_266498] Overall Response with Confirmation 
Unconfirmed Response 
(First Time Point) Confirmatory Response(Subsequent Time Point)  Best Overall Response of: 
CR CR CR 
CR PR SD, PD or PRa
CR SD SD or PDb
CR PD SD or PDb
CR NE SD or NEc
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SDb 
PR NE SDc 
NE NE NE 
BL = baseline; CR = complete response; NE = not evaluable; PD = disease progression; PR = partial 
response; SD = stable disease 
a: If a CR is truly met at first time point, then any reappearance of disease seen at a subsequent time 
point (including disease meeting PR criteria relative to BL) makes the disease PD at that time point 
b: Classify response as SD, provided that confirmato ry scan a minimum of 5 weeks later is still “SD.” 
Otherwise, response classified as PD. 
c: Classify response as SD, provided that confirmato ry scan a minimum of 5 weeks later is still “SD.” 
Otherwise, response classified as NE. 
 
Duration of Overall Response 
The duration of OR is measured from the date that measurement criteria are met for CR or PR (whichever 
status is recorded first) until the first date that recurrence or PD is objectively documented, taking as 
reference for PD the smallest sum LD recorded since the treatment started. 
Duration of Stable Disease 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266499] sum LD recorded since the treatment started. 
The clinical relevance of the duration of SD varies fo r different tumor types and grades. For this protocol, 
duration of stable disease is not being measured. 
Response Review 
For this Phase 2 study, response review will be perform ed at the site by [CONTACT_82163] 
(radiologist in conjunction with clinical investigator). 
Reporting of Results 
All subjects included in the study should be assessed for response to treatment, even if there are major protocol treatment deviations or if they are ineligible. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
67 
  
 
17.2. Appendix 2 - ECOG Performance Status Scale 
 
Score Status 
0 Fully active, able to carry on all predisease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature (e.g., light house work, office work) 
2 Ambulatory and capable of all self-care, but unable to carry out any work activities. 
Up and about more than 50% of waking hours. 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours. 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
5 Dead 
ECOG =Eastern Cooperative Oncology Group. 
Adapted from Oken MM et al. Am J Clin Oncol. 1982;5:649-5.  
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
68 
  
17.3. Appendix 3 - Cockcroft and Gault Formula 
 
Male (140-age) x weight (kg)  = XX mL/min Serum creatinine (mg/dL) x 72  
   
Female (140-age) x weight (kg)  = XX mL/min x 0.85 Serum creatinine (mg/dL) x 72  
. 
 
Adapted from Cockcroft DW et al. Nephron.  1976;16(1):31-41. Error! Bookmark not defined.  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
69 
  
17.4. Appendix 4 - [LOCATION_001] Heart Associat ion Cardiac Disease Classification 
The [LOCATION_001] Heart Association (NYHA) Cardiac Disease Classification provides a functional and 
therapeutic classification for the prescription of phys ical activity for cardiac subjects. Based on NYHA 
definitions, subjects are to be classified as follows:  
Class Definition 
Class I Subjects with no limitation of activities; they suffer no symptoms from ordinary activities. 
Class II Subjects with slight, mild limitation of activity; they are comfortable with rest or with mild 
exertion. 
Class III Subjects with marked limitation of ac tivity; they are comfortable only at rest. 
Class IV Subjects who should be at complete rest, c onfined to bed or chair; any physical activity 
brings on discomfort and symptoms occur at rest. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
70 
 17.5. Appendix 5 - Common Terminol ogy Criteria for Adverse Events (version 4.0) 
The National Cancer Institute’s CTCAE v 4.[ADDRESS_266500] be 
correlated with single-concept, MedDRA® terms. 
Grades in CTCAEs v 4.0 refer to the severity of the AE. Grades of 1 through 5, with unique clinical 
descriptions of severity for each AE, are based on this general guideline: 
 
Grade Status 
1 Mild: asymptomatic or mild symptoms; c linical or diagnostic observations only; 
intervention not indicated. 
2 Moderate: minimal, local, or noninvasive intervention indicated; limiting age-
appropriate instrumental ADL.a 
3 Severe or medically significant but not im mediately life-threatening: hospi[INVESTIGATOR_12342]; disabling, limiting self-care ADL.b 
4 Life-threatening consequences: urgent intervention indicated. 
5 Death related to adverse event. 
ADL = Activities of Daily Living 
a: Instrumental ADL refers to preparing meal s, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc. 
b: Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Cancer Therapy Evaluation Program, NCI CTCAE v 4.0. Available from http://ctep.cancer.gov/protocolDevelopment/ele ctronic_applications/docs/ctcaev 4.pdf
.  
 For further details regarding MedDRA, refer to the MedDRA website at: http://www.meddramsso.com. 
CTCAE v 4.0 is available online at: http://ctep.cancer.gov/protocolDevelopment/ele ctronic_applications/docs/ctcaev 4.pdf
. 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
71 
  
17.6. Appendix 6 – Quality of Life Surveys 
 
 
 
 
 
 
         Study ID: _______________ 
   
 
Quality of Life Assessment: 
 
 
DF/HCC 13-[ADDRESS_266501] Cancer: Evaluation of Effi cacy, Toxicity, and Patient-Reported 
Outcomes 
 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266502]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
2. In the last [ADDRESS_266503] loose or watery stools 
(diarrhea) ? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
 
 
3. In the last [ADDRESS_266504]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
   
4. In the last [ADDRESS_266505]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
5. In the last 7 days, how much did mouth 
or throat sores INTERFERE with your 
usual or daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
 6. In the last [ADDRESS_266506] nausea? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
 
 
7. In the last [ADDRESS_266507]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
8. In the last [ADDRESS_266508] vomiting? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
  
9. In the last [ADDRESS_266509]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
   
10. In the last [ADDRESS_266510] any hair 
loss? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
  
 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266511] arm or leg swelling ? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
 
 
12. In the last [ADDRESS_266512]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
13. In the last 7 days, how much did arm or 
leg swelling INTERFERES with your 
usual or daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
  
14. In the last [ADDRESS_266513] any 
rash: 
     Yes 
    No 
  
15. In the last [ADDRESS_266514]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
16. In the last 7 days, how much did 
fatigue, tiredness, or lack of energy 
INTERFERE with your usual or daily 
activities? 
     Not at all  
    A little bit  
     Somewhat      Quite a bit  
    Very much  
17. In the last [ADDRESS_266515] pain? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
 
 
18. In the last [ADDRESS_266516]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
   
19. In the last 7 days, how much did pain 
INTERFERE with your usual or daily 
activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
 
 
20. In the last [ADDRESS_266517]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
21. In the last 7 days, how much did 
decreased appetite INTERFERE with 
your usual or daily activities ? 
    Not at all  
    A little bit  
    Somewhat  
    Quite a bit  
    Very much  
 
  
 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266518]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
23. In the last 7 days, how much did 
problems with concentration 
INTERFERE with your usual or daily 
activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
 
 
24. In the last [ADDRESS_266519]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
25. In the last 7 days, how much did 
problems with memory INTERFERE 
with your usual or daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
  
26. In the last [ADDRESS_266520]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
  
27. In the last [ADDRESS_266521] a headache? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
 
 
28. In the last [ADDRESS_266522]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
29. In the last 7 days, how much did your 
headache INTERFERE with your usual 
or daily activities? 
    Not at all  
    A little bit  
    Somewhat  
    Quite a bit  
    Very much  
 
 
30. In the last [ADDRESS_266523]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
31. In the last 7 days, how much did 
numbness or tingling in your hands 
or feet INTERFERE with your usual or 
daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
 
 
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266524] 7 days, how OFTEN did you 
feel anxiety ? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
  
33. In the last [ADDRESS_266525]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
   
34. In the last 7 days, how much did 
anxiety INTERFERE with your usual or 
daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
  
35. In the last [ADDRESS_266526] sad or unhappy feelings? 
     Never  
    Rarely  
     Occasionally  
    Frequently  
    Almost constantly  
 
 
36. In the last [ADDRESS_266527]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
  
 37. In the last 7 days, how much did sad or 
unhappy feelings INTERFERE with 
your usual or daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
 
 
38. In the last [ADDRESS_266528]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
39. In the last 7 days, how much did 
insomnia including difficulty falling 
asleep, staying asleep, or waking up 
early INTERFERE with your usual or 
daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
 
 
40. In the last [ADDRESS_266529]? 
     None  
    Mild 
     Moderate  
    Severe  
    Very severe  
  
 
41. In the last 7 days, how much did 
shortness of breath INTERFERE with 
your usual or daily activities? 
     Not at all  
    A little bit  
     Somewhat  
    Quite a bit  
    Very much  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266530] pain.............................................................................      
I am bothered by [CONTACT_10167] e ffects of treatment ...........................      
I feel ill ...................................................................................      
I am forced to spen d time in bed ..........................................      
 
SOCIAL/FAMILY WELL-BEING  
 Not at 
all A little 
bit Some-
what Quite
a bit Very 
much
I feel close to my friends .......................................................     
I get emotional suppor t from my family .................................     
I get support from  my friends ................................................     
My family has ac cepted my illness .......................................     
I am satisfied with family communication about my illness ...     
I feel close to my partner (or the person who is my main support) .................................................................................      
I am satisfied with my sex life ...............................................      
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266531] my illness ....................     
I feel nervous .........................................................................     
I worry about dying ................................................................     
I worry that my condi tion will get  worse ................................     
 
  
FUNCTIONAL WELL-BEING  Not at 
all A little 
bit Some-
what Quite
a bit Very 
much
I am able to work (inc lude work at home) .............................     
My work (include work at home) is fulfilling ..........................     
I am able to enjoy life ............................................................     
I have accepted my illness ....................................................     
I am sleepi[INVESTIGATOR_102641]..................................................................     
I am enjoying the things  I usually do for fun .........................     
I am content with the qualit y of my life right now ..................     
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266532] certain parts of my body  where I experience pain .....      
  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266533] trouble walking ...........................................................      
 
  
 
 
Thank you for completing the survey! 
 
 
 
 
 
  
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266534] udy Calendar. The DNA blood plasma/serum samples 
will be collected at the same time blood samples are collected for the main study; therefore, there is no 
additional risk to the study participant. The site  staff will add the study center ID-subject number and 
collection time (hh:mm) to the tube. In addition, a sample sheet will be completed indicating the study ID, site number, subject number, visit number, and date and time of collection. Collection of the blood sample 
and informed consent will also be recorded in the subject’s eCRF. Frozen samples will be transferred 
from the central lab to a specialty laboratory for processing, analysis, and storage. 
 
Collection and Processing 
1 10ml EDTA tube will be collected at baseline for all participating patients. 
・ Freeze the whole tube at -80° C shortly after collection. 
・ Ship on dry ice. 
 
Samples will be shipped from sites in batches to the Laboratory of Bryan P. Schneider, MD for 
analysis. 
 
Laboratory of Bryan P. Schneider, M.D. 
Indiana Cancer Pavilion 
Walter Hall [ADDRESS_266535] Indianapolis, IN [ZIP_CODE] Phone: [PHONE_4707] 
Fax: [PHONE_4708] 
[EMAIL_4380]
 
 
. 
SECURITY OF THE SAMPLES , USE OF THE SAMPLES , RETENTION  OF THE SAMPLES 
Sample processing, including DNA/RNA extraction and genotypi[INVESTIGATOR_007], sequenc ing or other analysis will be 
performed by a local laboratory. Processing, analysis, and storage will be performed at a secure laboratory 
facility to protect the validity of the data and maintain subject privacy. Samples will be stored for up to 15 years after the completion of the study (defined as submission of the 
CSR to the appropriate regulatory agencies). At the e nd of the storage period, samples will be destroyed. 
Samples may be stored longer if a Health Author ity (or medicinal product approval agency) has active 
questions about the study. In this sp ecial circumstance,  the samples will be stored until the questions have 
been adequately addressed. 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266536] of future testing,  all samples collected will be single- or double-coded 
(according to the ICH15 guidelines) to maintain subject privacy. 
RIGHT TO WITHDRAW 
If, during the time the samples are stored, a partic ipant would like to withdraw his/her consent for 
participation in this research, the sponsor (DFCI) will destroy the samples, if they can still be identified 
(not anonymized). Once samples are anonymously labeled, it will not be possible to identify which 
samples have come from a particular individual. Therefore, it will not be possible to destroy those 
subject’s samples at that time. Information from any assays that have already been completed at the time 
of withdrawal of consent will continue to be used as necessary to protect the integrity of the research 
project. 
SUBJECT  PRIVACY AND RETURN OF DATA 
No information that identifies the subject (e.g., initials , date of birth, governme nt identifying number) will 
be associated with the sample. Samples that are processed for analysis (DNA/RNA extracted) may be 
double-coded. Double-coding involves removing the initia l code and replacing with another code such 
that the subject can be re-identified by [CONTACT_221849] c ode keys. The code keys are usually held by [CONTACT_221850]. The key linking the sample ID to the s ubject number will be maintained separately from the 
sample. At this point, the samples will be double-code d (the first code being the subject number) as long 
as the initial tube does not contain any personal identifiers or the random code assigned by [CONTACT_221851]. Laboratory personnel performing the genetic analysis will not have access to 
the “key.” Clinical data collected as part of the clinical trial will be cleaned of subject identifying 
information and linked by [CONTACT_3256] “key.” 
Sample anonymization may occur by [CONTACT_221852] “key.” Once the “key” is destroyed, it will not be 
possible to trace the pharmacogenomics assay results back  to an individual. The Principal Investigator 
[INVESTIGATOR_221806]. Data from subjects enrolled in this study ma y be analyzed worldwide, regardless of location of 
collection. 
The sponsor (DFCI) and its representatives and agen ts may share anonymous data with persons and 
organizations involved in the conduct or oversight of this research. These include: 
 Clinical research organizations retained by [CONTACT_456]; 
 Independent ethics committees or institutional revi ew boards that have responsibility for this 
research study; 
 National regulatory authorities or equivalent government agencies 
At the end of the analysis, results may be presented in a final report which can include part or all of the 
anonymous data, in listing or summary format. Othe r publications (e.g., in peer-reviewed scientific 
journals) or public presentations of the study results  will only include summaries of the study population, 
and no identified individual results will be disclosed. 
 
Given the exploratory nature of the planned analysis, it will not be possible to return individual data to 
subjects participating in the pharmacogenomics  research 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
82 
  
 
17.8. Appendix 8: Provider-Reported CTCAE Form 
INSTRUCTIONS: Provide the worst grade the patient has experienced in the last [ADDRESS_266537] 7 
days, mark “None”.   
Pt ID#_________            Pt Init:________            Visit#________            MRN#__________ 
 
System Organ Class (SOC) Adverse event None Grade 
1 Grade 
2 Grade 3 Grade 4 
Gastrointestinal Disorders Constipation      
Diarrhea      
Dry mouth      
Mucositis      
Nausea      
Vomiting      
General disorders and administration site 
conditions Hair Loss    NA NA 
Edema limbs      
Fatigue      
Pain      
Metabolism and nutrition 
disorders Anorexia      
Nervous system disorders Concentration 
impairment      
Dysgeusia      
Headache      
Peripheral sensory 
neuropathy      
Psychiatric disorders Anxiety      
Depression       
Insomnia      
Respi[INVESTIGATOR_696], thoracic and 
mediastinal disorders Dyspnea      
 Abbreviations: Not applicable  
 
Provider Signature:________________________________Date:________________ 
 
DF/HCC Sites: Please send this completed form to Danielle Gore: dgore@partners,org  
 External sites: Please send this completed form to the DFCI Coordinating Center: [EMAIL_4377]
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
83 
  
APPENDIX 9: DF/HCC  Multi-Center Data and Safety Monitoring Plan 
 
  
  
DFCI IRB Protocol #: 13-077  
         
 
                           
Protocol #: 13-077  
Version Date: 2/23/2016  
 
84 
  
TABLE OF CONTENTS   
1. INTRODUCTION .................................................................................................................. .......................... 85  
1.1.  Purpose ....................................................................................................................... .............................. 85  
1.2.  Multi-Center Data and Safety Monitoring Plan Definitions  .................................................................... 8 5 
2. GENERAL ROLES AND RE SPONSIBILITIES.......................................................................................... 86  
2.1.  DF/HCC Sp onsor ................................................................................................................ ..................... 86  
2.2.  Coordinating Center ........................................................................................................... ...................... 87  
2.3.  DF/HCC Quality Assurance Office fo r Clinical Trials (QACT) ............................................................... 87  
2.4.  Participating Institu tion ..................................................................................................... ...................... 87  
3. DF/HCC REQUIREMENTS FOR MULTI-CENTER PROTOCOLS ....................................................... 88  
3.1.  Protocol Di stribution ................................................................................................................................ 88  
3.2.  Protocol Revisions  and Closures ............................................................................................... ............... 88  
3.3.  Informed Consent Requirements ................................................................................................. .............. 89  
3.4.  IRB Docume ntation ............................................................................................................. ..................... 89  
3.5.  IRB Re-Approval ...................................................................................................................................... 90  
3.6.  Participant Confiden tiality and Authoriz ation Statement ......................................................................... 90  
3.7.  DF/HCC Multi-Center Protocol Registra tion Po licy .............................................................................. . 90 
3.8.  DF/HCC Protocol Case Number ................................................................................................... ........... 92 
3.9.  Protocol Deviations, Excep tions and Vi olations ................................................................................ ...... 92 
3.10. Safety Assessments and Toxicity Mo nitori ng .................................................................................... ........ 93 
3.11. Data Management ............................................................................................................... ..................... 94  
4. REQUISITIONING DRUG ........................................................................................................... ................. 95  
5. MONITORING: QUALITY CONTROL ................................................................................................... ... 95 
5.1.  Ongoing Monitoring of Protocol Co mpliance ..................................................................................... ..... 95 
5.2.  Evaluation of Participatin g Institution Pe rformance ........................................................................... .... 95 
6. AUDITING: QUALITY ASSURANCE ................................................................................................... ...... 96 
6.1.  DF/HCC Sponsored  Trials ....................................................................................................... ................ 96  
6.2.  Participating Institu tion ..................................................................................................... ...................... 96  
6.3.  DF/HCC Sponsor and Co ordinating Center ........................................................................................ .... [ADDRESS_266538] Performance ...................................................................................................... ................ 97  
  
  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
85 
  
1. INTRODUCTION 
 
The Dana-Farber/Harvard Cancer Center Multi-Center Data and Safety Monitoring Plan 
(DF/HCC DSMP) outlines the procedures for conducting a DF/HCC Mu lti-Center research 
protocol. The DF/HCC DSMP shou ld serve as a reference for any sites external to DF/HCC 
that will be participating in the research protocol. 
 
1.1. Purpose 
 
To establish standards that will ensure that  a Dana-Farber/Harvard Cancer Center Multi-
Center protocol will comply with Federal Regulations, Health Insurance Portability and 
Accountability Act (HIPAA) requirements and applicable DF/HCC Standard Operating 
Procedures, and Cancer Therapy Ev aluation  Program (CTEP) Multi-Center Guidelines.        
 
1.2.  Multi-Center Data and Safety Monitoring Plan Definitions 
 
DF/HCC Multi-center Protocol :  A research protocol in which one  or more outside 
institutions are collaborating with Dana-Far ber/Harvard Cancer Center where  a DF/HCC 
investigator is the sponsor. DF/HCC includes Dana-Farber/Partners Cancer Care (DF/PCC) 
Network Clinical Trial Affiliates.   Lead Institution:  One of the  Dana-Farber/Harvard Cancer Center consortium members 
(Dana-Farber Cancer Institute (DFCI), [LOCATION_005] General Hospi[INVESTIGATOR_307] (MGH), Beth Israel Deaconess Medical Center (BIDMC), Children’s Hospi[INVESTIGATOR_7724] (CHB), Brigham 
and Women’s Hospi[INVESTIGATOR_307] (BWH)) responsible for the coordination, development, 
submission, and approval of a protocol as well as its subsequent amendments per the 
DFCI IRB and applicable regulatory guideline s.  The Lead Institution is typi[INVESTIGATOR_221807]/HCC Sponsor. The Lead In stitution also typi[INVESTIGATOR_221808] /HCC Multi-Center Protocol.   
 DF/HCC Sponsor:  The person sponsoring the submitted Multi-Center protocol.  Within 
DF/HCC, this person is the Overall Principa l Investigator who ta kes responsibility for 
initiation, management and conduct of the protocol  at all research loca tions. In applicable 
protocols, the DF/HCC Sponsor will serve as the single liaison with any regulatory agencies. The DF/HCC Sponsor has ultimate authority over the protocol and is responsible for the conduct of the study at DF/HCC and all Pa rticipating Institutions. In most cases the 
DF/HCC Sponsor is the same person as the DF/HCC Principal Investigator; however, both 
roles can be filled by [CONTACT_57945]. 
 
Participating Institution:  An institution that is outside the DF/HCC and DF/PCC 
consortium that is collabor ating with DF/HCC on a protoc ol where the sponsor is a 
DF/HCC Investigator.  The Participating Institution ac knowledges the DF/HCC Sponsor 
as having the ultimate authorit y and responsibility for the overa ll conduct of the study.    
Protocol #: 13-077  
Version Date: 2/23/2016  
 
86 
  
Coordinating Center: The entity (i.e. Lead Institution) that provides administrative 
support to the DF/HCC Sponsor in order th at he/she may fulfill the responsibilities 
outlined in the protocol document and DSMP, a nd as specified in applicable regulatory 
guidelines. In general, the Lead Institution is the Coordinating Center for the DF/HCC 
Multi-Center Protocol. Should the DF/HCC Sponso r decide to use a CRO, the CRO will be 
deemed the Coordinating Center.   
 DF/HCC Quality Assurance Office for Clinical Trials: A unit within DF/HCC 
developed to computerize and manage data, an d to provide a Quality Control and Quality 
Assurance function for DF/HCC trials .   
 
2. GENERAL ROLES AND RESPONSIBILITIES 
For DF/HCC Multi-Center Protocols, the DF/HCC Sponsor, the Coordinating Center, and 
the Participating Institutions are expected to adhere to the following general responsibilities:  
 
2.1. DF/HCC Sponsor 
 The DF/HCC Sponsor, [CONTACT_221863],  will accept responsibility for all aspects of 
conducting a DF/HCC Multi-Center protocol wh ich includes but is not limited to:  
 Oversee the coordination, development, submission, and approval of the protocol 
as well as subsequent amendments.  
 Ensure that the investigators, study team  members, and Participating Institutions 
are qualified and appropriately resour ced to conduct the protocol.   
 Submit the Multi-Center Data and Safety M onitoring Plan as an appendix to the 
protocol. 
 Assure all Participating Institutions are using the correct vers ion of the protocol. 
 Ensure that each participating investigat or and study team receives adequate 
protocol training and/or a Site Initiation Visit prior to enrolling participants and 
throughout trial’s c onduct as needed. 
 Ensure the protocol will be provided to each particip ating site in a language 
understandable to all site personnel when English is not the primary language.  
 Monitor progress and overall conduct of the study at all Participating Institutions.  
 Ensure all DFCI Institutional Review Bo ard (IRB), DF/HCC and other applicable 
reporting requirements are met.  
 Review data and maintain timely subm ission of data for study analysis.  
 Ensure compliance with all requirements as set forth in the Code of Federal 
Regulations, applicable DF/HCC require ments, HIPAA requirements, and the 
approved protocol. 
 Commit to the provision that the protocol  will not be rewritten or modified by 
[CONTACT_57946]/HCC Sponsor. 
 Identify and qualify Participating Institutions and obtain accrual commitments prior to extending the prot ocol to that site.  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
87 
  
 
2.2. Coordinating Center  
 The Coordinating Center will assume the following general responsibilities: 
 Assist in protocol development  
 Maintain copi[INVESTIGATOR_221809] (IRB) 
approvals from all Participating Institutions. 
 Maintain updated roster  of participants.  
 Verify eligibility. 
 Verify response. 
 Oversee the data collection proce ss from Participating Institutions. 
 Maintain documentation of Serious Adverse Event (SAE) reports submitted by 
[CONTACT_221853]/HCC Sponsor for timely review.   
 Distribute adverse events reported to  the DF/HCC Sponsor that fall under the 
DFCI IRB Adverse Event Reporting Policy to all participati ng investigators. 
 Provide Participating Institutions w ith information regarding DF/HCC 
requirements that they will be expected to comply with.   
 Monitor Participating Institutions eith er by [INVESTIGATOR_2394]-site or virtual monitoring.  
 Maintain Regulatory documents of all Participating Institutions.  
 Conduct regular communications  with all Participating Institutions (conference 
calls, emails, etc).  
 Maintain documentation of all communications. 
 Ensure that each Participating Institution ha s the appropriate assurance on file with 
the Office of Human Research  Protection (OHRP).     
 
2.3. DF/HCC Quality Assurance Office for Clinical Trials (QACT) 
 
In addition to the Coordinating Center , the DF/HCC QACT provides the following 
support services to assi st the DF/HCC Sponsor: 
 Develop protocol specific case report forms (eCRFS). 
 QA/QC data of protocol specific CRFs.  
 Provide a central participan t registration, which includes review of consent and 
eligibility. 
 Provide auditing services (funding and QACT approval required). 
 
2.4. Participating Institution 
 
Each Participating Institution is expected to 
comply with all applicable Federal 
Regulations and DF/HCC requirements, the protocol and HIPAA requirements. All 
Participating Institutions will pr ovide a list of personnel assign ed to the role for oversight 
of data management at their s ite to the Coordinating Center.  
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
88 
 The general responsibilities for each Part icipating Institution are as follows: 
 Commit to the accrual of participants to the protocol. 
 Submit protocol and/or amendm ents to their local IRB. 
 Maintain a regulatory binder in a ccordance with DF/HCC requirements. 
 Provide the Coordinating Center with regulatory documents as requested. 
 Participate in protocol trai ning prior to enroll ing participants and throughout the 
trial as needed (i.e. teleconferences). 
 Update Coordinating Center with res earch staff changes on a timely basis. 
 Register participants thr ough the Coordinating Center.  
 Submit source documents, research reco rds, and CRFs per protocol specific 
submission guidelines to the Coordinating Center. 
 Submit Serious Adverse Event (SAE) report s to local IRB per local requirements 
and to the Coordinating Center, in acco rdance with DF/HCC requirements. For 
CTEP trials, submit SAE reports directly  to CTEP and provide copi[INVESTIGATOR_221810]  
 Submit protocol deviations and violations to local IRB per local requirements and 
to the DF/HCC Sponsor in accordance with DF/HCC requirements. 
 Secure and store investigational agents and/or other protocol  mandated drugs per 
federal guidelines and protocol requirements. 
 Have office space, office equipment, and internet access that meet HIPAA standards. 
 
3. DF/HCC REQUIREMENTS FOR MULTI-CENTER PROTOCOLS 
  
The following section will clarify DF/HCC Require ments and further detail the expectations 
for participating in a DF/HCC Multi-Center protocol.  
 
3.1. Protocol Distribution 
 
The Coordinating Center will distribute the final DFCI IR B approved protocol and any 
subsequent amended protocols to all Participating Institutions.    
 
3.2. Protocol Revisions and Closures 
 The Participating Institutions will receive not ification of protocol revisions and closures 
from the Coordinating Center.  It is the individual Participa ting Institution’s responsibility 
to notify its IRB of these revisions. 
 
 Non life-threatening revisions:  Participating Institutions will receive written 
notification of protocol re visions regarding non life-th reatening events from the 
Coordinating Center. Non-life-threaten ing protocol revisions must be IRB 
approved and 
implemented within 90 days from receipt of the notification. 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
89 
  Revisions for life-threatening causes: Participating Institu tions will receive 
immediate notification from the Coordinating Center concerning protocol revisions 
required to protect lives w ith follow-up by [CONTACT_6791], mail, e-mail, etc.  Life-threatening 
protocol revisions will be implemente d immediately followed by [CONTACT_57947]. 
 
 Protocol closures and temporary holds:  Participating Institutions will receive 
notification of protocol closures and temporary hol ds from the Coordinating 
Center. Closures and holds  will be effective immediately.  In addition, the 
Coordinating Center, will update the Par ticipating Institutions on an ongoing basis 
about protocol accrual data so that they will be aw are of imminent protocol 
closures. 
 
3.3. Informed Consent Requirements 
 
The DF/HCC approved informed consent doc ument will serve as a template for the 
informed consent for Participating Institutions. The Participating Institution consent form must follow the consent template as closely as possible and should adhe re to specifications 
outlined in the DF/HCC Guidance Document on Model Consent Language for PI-Initiated 
Multi-Center Protocols.  This document will be  provided separately to each Participating 
Institution.  Participating Institutions are to send their version of the informed consent document and HIPAA authorization, if a separate document , to the Coordinating Center for review and 
approval prior to submission to their local IRB. The approved consent form must also be submitted to the Coordinating Center after approval by [CONTACT_1036].  The Principal Investigator (PI) at each Participating Instit ution will iden tify the physician 
members of the study team who will be obtaining consent and signing the consent form for therapeutic protocols. Participating inst itutions must follow the DF/HCC requirement 
that only attending physicians obtain informed consent and re-consent to interventional trials (i.e. drug and/or  device trials).   
 
3.4. IRB Documentation 
 The following must be on file with the Coordinating Center: 
 Approval letter of the Participating Institution's IRB  
 Copy of the Informed Consent Form a pproved by [CONTACT_57949]’s 
IRB  
 Participating IRB’s approval for all amendments 
 
It is the Participating Instituti on's responsibility to notify its IRB of protocol amendments.  
Participating Institutions will have 90 days from receipt to provide the Coordinating 
Center their IRB approval for am endments to a protocol.    
 
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266539] ( HIPAA). Any 
information, related to the physical or mental health of an individual is called Protected 
Health Information (PHI). HIPAA outlines how and under what circumstances PHI can be 
used or disclosed.   In order for covered entities to use or disclo se protected health in formation during the 
course of a study, the study par ticipant must sign an Author ization.  This Authorization 
may or may not be separate from the info rmed consent document.  The Coordinating 
Center, with the approval from the DFCI IRB, will provide a consent template, which covered entities (Participati ng Institutions) must use.  
 The DF/HCC Sponsor will use all efforts to limit its use of protected health information in 
its trials.  However, because of the nature  of these trials, certain protected health 
information must be collected per NCI requi rements. These are the primary reasons why 
DF/HCC has chosen to use Authorizations, sign ed by [CONTACT_89438], rather 
than limited data sets with data use agreements. 
 
3.6.1.  DF/HCC Multi-Center Prot ocol Confidentiality 
 
All documents, investigative reports, or inform ation relating to the participant are strictly 
confidential. Whenever reasona bly feasible, any participant specific reports (i.e. Pathology 
Reports, MRI Reports, Operative Reports, etc.) submitted to the Coordinating Center must 
have the participant’s full name & social s ecurity number “blacked out” and the assigned 
DF/HCC QACT case number (as described be low) and DF/HCC prot ocol number written 
in (with the exception of the signed informed consent document). Participant initials may 
only be included or retained for cr oss verification of identification 
 
3.7. DF/HCC Multi-Center Protocol Registration Policy  
 
3.7.1.  Participant Registration  and Randomization  
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266540] 
Manager at [EMAIL_4377]  or by [CONTACT_60839] [PHONE_4703]:  
 Copy of required  laboratory tests including: Hematology (CBC w/differential), 
Serum Chemistries, and a pregnancy test (for women of child-bearing potential 
only)  
 Signed informed consent document 
 HIPAA authorization form (if separate from the informed consent document)  
 Completed QACT Eligibility Checklist  
 Radiology Report of tumor assessments  
 Pathology report with document ation of ER, PR, and HER2  
 Clinic note documenting hist ory and physical examination  
 ECG report  
 The Coordinating Center will review the submitted documents in order to verify 
eligibility and consent.  To complete the registration process, the Coordinating Center 
will: 
 Register the participant on the study with the DF/HCC QACT 
 Upon receiving confirmation of registrati on by [CONTACT_221854], the Coordinating Center 
will inform the Participating Institution a nd provide the study specific participant 
case number, and if applicable the dose treatment level.  
 Treatment may not begin without confir mation from the Coordinating Center 
that the participant has been registered.  
 Randomization can only occur during QAC T’s normal business hours, Monday through 
Friday from 8:00 AM to 5:[ADDRESS_266541] be registered with the DF/HCC QACT befo re receiving study treatment.  
Treatment may not be initiated until the Partic ipating Institution receiv es a faxed or e-mail 
copy of the participant’s regi stration confirmation memo fr om the Coordinating Center. 
Therapy must be initiated per protocol gui delines.  The DF/HCC Sponsor and DFCI IRB 
must be notified of any exceptions to this policy.  
3.7.3.  Eligibility Exceptions 
 The DF/HCC QACT will make no exceptions to the eligibility requirements for a protocol without DFCI IRB approval. The DF/HCC QACT requires each institution to fully 
comply with this requirement. 
 
3.7.4.  Verification of Registration, Do se Levels, and Arm Designation 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
92 
 A registration confirmation memo for partic ipants registered to DF/HCC Multi-Center 
Protocol will be faxed or emailed to the registering institution with in one business day of 
the registration. 
 Treatment may not be initiated until the site receives a faxed or e-mailed copy of the registration confirmation memo. 
 
3.8. DF/HCC Protocol Case Number  
 
Once eligibility has been established and the participant successfully registered, the 
participant is assigned a five digit protocol  case number.  This number is unique to the 
participant on this trial and must be  used for QACT eCRF completion and 
correspondence, and correspondence with the Coordinating Center.   
 
3.9. Protocol Deviations, Exceptions and Violations  
 
Federal Regulations require an IRB to review proposed change s in a research activity to 
ensure that researchers do not initiate cha nges in approved research without IRB review 
and approval, except when necessary to el iminate apparent immediate hazards to the 
participant. DF/HCC requires all departures from the defined procedures set forth in the IRB approved protocol to be reported to the DF/HCC Sponsor, who in turn is responsible 
for reporting to the DFCI IRB.  For reporting purposes, DF/HCC uses the terms “violation”, “deviation” and “exception” 
to describe derivations from a protocol. All Pa rticipating Institutions must adhere to these 
requirements for reporting to the DF/HCC Sp onsor and will follow their institutional 
policy for reporting to their local IRB. 
 
3.9.1.  Definitions 
 
Protocol Deviation
: Any departure from the defined procedures set forth in the IRB-
approved protocol which is prospectively approved  prior to its implementation. 
 Protocol Exception
:  Any protocol deviation that relate s to the eligibility criteria, e.g. 
enrollment of a participant who does not meet all inclusion/exclusion criteria. 
 Protocol Violation
: Any protocol deviation that was not prospectively approved  by [CONTACT_221855].   
 
3.9.2.  Reporting Procedures 
 
DF/HCC Sponsor:  is responsible for ensu ring that clear documenta tion is available in the 
medical record and/or regulatory documents to describe all protocol exceptions, deviations 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
93 
 and violations. The DF/HCC Sponsor will al so be responsible fo r ensuring that all 
protocol violations/deviati ons are promptly reported per DFCI IRB guidelines.  
 
Participating Institutions : Protocol deviations require pr ospective approval from the DFCI 
IRB. The Participating Institution must subm it the deviation request to the Coordinating 
Center who will then submit the deviation request to the DFCI IRB. Upon DFCI IRB 
approval the deviation is submitted to the Par ticipating Institution IRB, per institutional 
policy. A copy of the Participating Institut ion’s IRB report and determination will be 
forwarded to the Coordinating Center with in [ADDRESS_266542] be sent to the Coordinating Center in a timely manner.  
 Coordinating Center:
  Upon receipt of the violation/devi ation report from the Participating 
Institution, the Coordinating Center will s ubmit the report to the DF/HCC Sponsor for 
review. Subsequently, the Participating Institu tion’s IRB violation/deviation report will be 
submitted to the DFCI IRB for review per DFCI IRB reporting guidelines.  
 
3.10. Safety Assessments and Toxicity Monitoring  
 
The study teams at all particip ating institutions ar e responsible for protecting the safety, 
rights and well-being of study participants. Recording and repor ting of adverse events that 
occur during the course of a study help ensure the continuing safety of study participants.   All participants receiving investigational agen ts and/or other protocol mandated treatment 
will be evaluated for safety.   The safety parameters include all laboratory tests and 
hematological abnormalities, physical examinat ion findings, and spontaneous reports of 
adverse events reported by [CONTACT_4317].  All to xicities encountered during the study will 
be evaluated according to the NCI criteria specified in the protocol. Life-threatening 
toxicities must be reported immediately to the DF/HCC Sponsor via the Coordinating 
Center.  
 
Additional safety assessments and toxicity monitoring will be outlined in the protocol. 
 
3.10.1.  Guidelines for Reporting Serious Adverse Events  
 
Guidelines for reporting Adverse Events (A Es) and Serious Adverse Events (SAEs) are 
detailed in protocol section [ADDRESS_266543] report the AEs to the DF/HCC Sponsor and the 
Coordinating Center following the DF CI IRB SAE Reporti ng Requirements.  
 
The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and be responsible  for communicating to all participating 
investigators, any observations reportable under the DFCI IRB Repor ting Requirements.  
Protocol #: 13-077  
Version Date: 2/23/2016  
 
94 
 Participating Investigators will  review any distributed AE reports, send a copy to their 
IRB according to their local IRB’s policies an d procedures, and file a copy with their 
regulatory documents. 
 
3.10.2.  Guidelines for Processing  IND Safety Reports  
 
FDA regulations require sponsors of clin ical studies to notify the FDA and all 
participating investigators of any adverse e xperience associated with the use of the 
investigational agent that is both serious  and unexpected. The DF/HCC Sponsor will 
review all IND Safety Reports and ensure that  all IND Safety Reports are distributed to 
the Participating Institutions.  The Participa ting Institutions will review and submit to their 
IRB according to their institutional policies and procedures. 
 
3.11. Data Management 
The DF/HCC QACT develops a set of electron ic case report forms eCRFs, for use with 
the protocol.  These forms are designed to collect data for each study. The DF/HCC QACT provides a web based training for eCRF users. 
   
3.11.1.  Data Forms Review 
 
When data forms arrive at the DF/HCC QAC T, they are reviewed for completeness, 
protocol treatment compliance, adverse events (toxicities) and response. Data submissions 
are monitored for timeliness and completeness of submission. Particip ating Institutions are 
notified of their data submission delinque ncies in accordance with the following: 
 Incomplete or Questionable Data
 
If study forms are received with missing or questionable data, the submitting institution 
will receive a written or electronic query fr om the DF/HCC QACT Data  Analyst or study 
monitor.  Responses to all queries should be completed and submitted within 14 calendar 
days.  Responses may be returned on the written query or on an amended paper case report form, or in the case of electronic queries, with in the electronic data capture (eDC) system. 
In the case of a written query for data submitted on a paper case report form, the query must be attached to the specific data  being re-submitted in response.   
 Missing Forms
 
If study forms are not submitted on schedule, th e Participating Institution will receive a 
Missing Form Report from the Coordinating Center noting the missing forms.  These reports are compi[INVESTIGATOR_163871]/HCC QACT and distributed a minimum of four times a 
year.  
    
Protocol #: 13-077  
Version Date: 2/23/[ADDRESS_266544] itutions are responsible for 
ordering their own supply of Eribulin.  Please refer to the protocol section 7.1 for more 
information. 
 
 
5. MONITORING: QUALITY CONTROL 
  
The quality control process for a clinical trial requires verification of protocol compliance and data accuracy. The Coordinating Center, with the aid of the QACT provides quality 
control oversight for the protocol. 
 
5.1. Ongoing Monitoring of Protocol Compliance 
 
The Coordinating Center will implement ongoi ng monitoring activities to ensure that 
Participating Institutions are complying with regulatory and protocol requirements, data 
quality, and participant safety.  Monitoring wi ll occur before the clinical phase of the 
protocol begins, continue during protocol performance and through study completion. 
Additional monitoring practices  may include but are not li mited to; source verification, 
review and analysis of the following: eligibility requirements of all participants, informed consent procedures, adverse events and all associated documentation, study drug 
administration/treatment, regulat ory files, protocol deviatio ns, pharmacy records, response 
assessments, and data management. Additionally, a plan will be formulated to provide regular and ongoing communicatio n to Participating Institu tions about study related 
information which will include participati on in regular coordinating center initiated 
teleconferences. Teleconferences will occur approximately every other week beginning 
once sites are active and will continue regul arly until the completion of accrual. Upon 
completion of accrual, teleconferences will o ccur quarterly thereafter (unless otherwise 
specified by [CONTACT_36476]) until study completion.  Additional communication may 
be distributed via “New sletters” or email as deemed appr opriate by [CONTACT_407].  
 
On-site and virtual monitoring will occur as  specified in the study monitoring plan.  
Monitoring will be performed by [CONTACT_221856]’s Clinical Research Specialist 
(CRS).  The Participating Institutions will be  required to submit de-identified participant 
source documents to the Coordinating Center for virtual monitoring visits.  The data will be reviewed for completeness, quality, and a dherence to the protocol requirements. Sites 
will be asked to provide source documentation via fax, email, or mail as specified by [CONTACT_221857] m onitoring visits. A virtua l site initiation (SIV) 
will be conducted with each pa rticipating site prior to study activation. Participating sites 
may not begin enrolling until an SIV has occurred. 
 
5.2. Evaluation of Participating Institution Performance 
 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
96 
 5.2.1.  Monitoring Reports 
 
The DF/HCC Sponsor will review  all monitoring reports for on-site and virtual monitoring 
of Participating Institutions to ensure protocol compliance and ability to fulfill 
responsibilities of particip ating in the study. The DF/HCC  Sponsor may increase the 
monitoring activities at Partic ipating Institutions that are unable to comply with the 
protocol, DF/HCC Sponsor requirements or fe deral and local regulations. Participating 
Institutions may also be subject to an audit as determined by [CONTACT_57954]/HCC Sponsor. 
 
6. AUDITING: QUALITY ASSURANCE 
 
Auditing is a method of Quality Assurance. Its main focus is to measure whether standards 
and procedures were followed. Auditing is the systematic and independent examination of 
all trial related activities and documents.  Au dits determine if evaluated activities were 
appropriately conducted and whether data wa s generated, recorded and analyzed, and 
accurately reported per the protocol, Standard Operating Procedures (SOPs), and the Code 
of Federal Regulations (CFR). 
 
6.1. DF/HCC Sponsored Trials 
 
Annual on-site audits will be scheduled by [CONTACT_221858]. Approximately 3-[ADDRESS_266545] records may be audited.Also, an audit may be triggered if 
deficiencies are noted related to consent practices, eligibility, missing, incomplete, or 
questionable data submission, non-compliance or any other issue the protocol chair deems appropriate for audit.  
 
6.2. Participating Institution 
 
It is the Participating Institution’s responsibility to notify the Coordinating Center of all 
scheduled audit dates (interna l or external) and re-audit dates (if applicable), which 
involve this protocol. All institutions will fo rward a copy of final audit and/or re-audit 
reports and corrective action plans (if appli cable) to the Coordinating Center, within 12 
weeks after the audit date.  
 
6.3. DF/HCC Sponsor and Coordinating Center  
 
The DF/HCC Sponsor will review  all final audit reports and corrective action plans if 
applicable. The Coordinating Center, must forward these reports to the DF/HCC QACT 
per DF/HCC policy for review by [CONTACT_57954]/HCC Audit Committee. Based upon the audit 
assessments the DF/HCC Audit Committee c ould accept or conditionally accept the audit 
rating and final report. Conditional approva l could require the DF/HCC Sponsor to 
implement recommendations or require furt her follow-up.  For unacceptable audits, the 
Protocol #: 13-077  
Version Date: 2/23/2016  
 
97 
 DF/HCC Audit Committee would forward the fina l audit report and co rrective action plan 
to the DFCI IRB as applicable. 
 
6.4. Sub-Standard Performance 
 
The DF/HCC Sponsor and DFCI IRB, is char ged with considering the totality of an 
institution’s performance in considering institutional participation in the protocol. 
 
6.4.1.  Corrective Actions 
 
Participating Institutions that fail to meet the performance goals of accrual, submission of 
timely accurate data, adherence to protocol requirements, and compliance with state and 
federal regulations, will be recommended for a six-month probation period. Such 
institutions must respond with a corrective action plan and must demonstrate during the 
probation period that deficien cies have been corrected, as evidenced by [CONTACT_57955]. Particip ating Institutions that fail to demonstrate significant 
improvement will be considered by [CONTACT_57954]/H CC Sponsor for revocation of participation. 
 
Protocol #13-077  D:2/22/2013 KAJ; F: 5/13/2013 LK 
 DANA-FARBER CANCER INSTITUTE 
Nursing Protocol Education Sheet 
Protocol Number: 13-077 
Protocol Name: A Phase [ADDRESS_266546] Cancer:  
Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes 
DFCI Site PI: [INVESTIGATOR_221811], MD, MPH 
DFCI Research Nurse: Peg Haldoupis, RN; Liz Kasparian, RN; Mary O’Dr iscoll, RN; Kathy [COMPANY_002], RN; Myra St. Amand, 
RN, Beth Tiani, RN 
Page the DFCI research nurse or DFCI site PI [INVESTIGATOR_143004]/concerns about the protocol.   
Please also refer to ONC 15 : Oncology Nursing Protocol Education Policy 
*** Remember to check the ALERT PAGE*** 
              SPECIAL NURSING CONSIDERATIONS UNIQUE TO THIS PROTOCOL Study Design 
 Eribulin  is a synthetic derivative of the natural product halic hondrin B, which is isolated from a marine sponge.  
Halichondrin B exhibits anti-cancer activity through a microtubule-destabilizing anti-mitotic mechanism of action.  
Eribulin exerts its effects by [CONTACT_221859].  This interference leads to cell death via apoptosis.  Study Design : Participants will be enrolled in 2 parallel cohorts.  
Cohort 1 = HR+/HER2-- and Cohort 2 = HR- - and HER2-- (TNBC) – Section 1.1; Study Rationale – Section 2.5  A 
cycle is 3 weeks (21 days) – Section 5.3 Dose 
Calc.  Eribulin  dosing is calculated in mg/m2 – Section 5.4 
 BSA is calculated on each treatment day according to institutional standard – Please review Section 5.4  Study Drug  
Administration Eribulin  Administration  Guidelines are found in Sections 5.4 and 7 
 IV, administered over approximately 2 to 5 mi nutes on Days 1 and 8 of each 3 week cycle 
 May be injected directly as an IV infusion over approxi mately 2 to 5 minutes or diluted in up to 100mL 0.9% 
saline for IV infusion over approximately 2 to 5 minutes.  NOT compatible with solutions containing dextrose . 
 No special tubing is required for administration 
 Do not administer in the same IV line concurrent with other medicinal products 
 Criteria to treat: See Section 5.4 
 Dose 
Modifications 
& Toxicity Dose Modifications/Dosing Delay for Toxicity  are outlined in Section 6 
 This protocol uses NCI CTCAE criteria, version 4.0 – Section 13.1 
 Expected toxicities are outlined in Section 6.1 
 Dose modifications and delays are outlined in Section 6.2 and Table 1 
 If Day [ADDRESS_266547] be NO SOONER than 14 days later 
 Concomitant 
Meds Concomitant Therapy  Guidelines are in Section 5.6 
 Permitted meds/therapi[INVESTIGATOR_221812] 5.6.2 
 Prohibited meds/therapi[INVESTIGATOR_221812] 5.6.3 
 Information on potential drug-drug interactions is in Section 5.6.4 Required  
Data  Study Calendar and Assessment Required data  are outlined in Sections 5.5, 9 and 10.5 – 10.7 
 Please refer to Table [ADDRESS_266548] administration time. 
Please be sure to DOCUMENT study medication actual  UP/DOWN times in medical record (e.g. LMR, eMAR, 
nursing notes). Edit eMAR as needed to match the exact time given . 
 If there is a discrepancy in the infusion time, delay in administration, or the infusion takes longer than is 
permitted by [CONTACT_152038], please document the reason for the discrepancy in the medical 
record.  
Please be sure to also DOCUMEN any additional vital si gns, routes of administration, or injection sites 
 